[go: up one dir, main page]

EP4500178A1 - Normalisierung räumlicher antikörperdaten - Google Patents

Normalisierung räumlicher antikörperdaten

Info

Publication number
EP4500178A1
EP4500178A1 EP24740635.8A EP24740635A EP4500178A1 EP 4500178 A1 EP4500178 A1 EP 4500178A1 EP 24740635 A EP24740635 A EP 24740635A EP 4500178 A1 EP4500178 A1 EP 4500178A1
Authority
EP
European Patent Office
Prior art keywords
analyte
capture
probe
subset
analyte capture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24740635.8A
Other languages
English (en)
French (fr)
Inventor
Govinda M. KAMATH
Stephen R. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
10X Genomics Inc
Original Assignee
10X Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 10X Genomics Inc filed Critical 10X Genomics Inc
Publication of EP4500178A1 publication Critical patent/EP4500178A1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies

Definitions

  • This specification describes technologies relating to analyte data normalization, particularly for use in analyzing spatial analyte data.
  • Cells within a tissue have differences in cell morphology and/or function due to varied analyte levels (e.g., gene and/or protein expression) within the different cells.
  • the specific position of a cell within a tissue e.g., the cell’s position relative to neighboring cells or the cell’s position relative to the tissue microenvironment
  • Spatial analysis of an analyte within a biological sample may require determining the sequence of the analyte sequence or a complement thereof and the sequence of the spatial barcode or a complement thereof to identify the location of the analyte.
  • the biological sample may be placed on a solid support to improve specificity and efficiency when being analyzed for identification or characterization of an analyte, such as protein, DNA, RNA or other genetic material, within the sample.
  • Some embodiments of the present disclosure are directed to methods, compositions, devices, and systems for determining the location and/or abundance of an analyte in a biological sample. Determining the spatial location and/or abundance of analytes (e.g., proteins, DNA, or RNA) within a biological sample leads to better understanding of spatial heterogeneity in various contexts, such as disease models. Described herein are methods for capturing probes and/or barcodes to a capture domain. In some instances, the techniques disclosed herein facilitate downstream processing, such as sequencing of the probes and/or barcodes bound to a capture domain.
  • analytes e.g., proteins, DNA, or RNA
  • the methods, compositions, devices, and systems disclosed herein utilize RNA-templated ligation (RTL) for analyzing an analyte (e.g., RNA) in a biological sample.
  • RTL RNA-templated ligation
  • analyte e.g., RNA
  • analyte capture agents are used for analyzing an analyte (e.g., protein) in a biological sample.
  • the methods disclosed herein allow spatial analysis of two or more different types of analytes, e.g., protein and nucleic acids concurrently.
  • a method for analyzing an analyte in a biological sample mounted on a first substrate comprising: hybridizing a first probe oligonucleotide and a second probe oligonucleotide to the analyte, wherein the first probe oligonucleotide and the second probe oligonucleotide each comprise a sequence that is substantially complementary to adjacent sequences of the analyte, and wherein the second probe oligonucleotide comprises a capture probe binding domain; coupling the first probe oligonucleotide and the second probe oligonucleotide, thereby generating a connected probe; aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises: (i) a spatial barcode and
  • the first probe oligonucleotide and the second probe oligonucleotide are on a contiguous nucleic acid sequence. In some instances, the first probe oligonucleotide is on the 3’ end of the contiguous nucleic acid sequence. In some instances, the second probe oligonucleotide is on the 5’ end of the contiguous nucleic acid sequence. In some instances, the adjacent sequences abut one another. In some instances, the adjacent sequences are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides away from one another.
  • the methods further include generating an extended first probe oligonucleotide, wherein the extended first probe oligonucleotide comprises a sequence complementary to a sequence between the sequence hybridized to the first probe oligonucleotide and the sequence hybridized to the second probe oligonucleotide.
  • the methods further include generating an extended second probe oligonucleotide using a polymerase, wherein the extended second probe oligonucleotide comprises a sequence complementary to a sequence between the sequence hybridized to the first probe oligonucleotide and the sequence hybridized to the second probe oligonucleotide.
  • the methods further include contacting the biological sample with a reagent medium comprising a permeabilization agent and an agent for releasing the connected probe, thereby permeabilizing the biological sample and releasing the connected probe from the analyte.
  • the agent for releasing the connected probe comprises a nuclease.
  • the nuclease comprises an RNase, optionally wherein the RNase is selected from RNase A, RNase C, RNase H, or RNase I.
  • the permeabilization agent comprises a protease.
  • the protease is selected from trypsin, pepsin, elastase, or proteinase K.
  • the reagent medium further comprises a detergent.
  • the detergent is selected from sodium dodecyl sulfate (SDS), sarkosyl, saponin, Triton X-100TM, or Tween-20TM.
  • the reagent medium comprises less than 5 w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium comprises at least 5% w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium does not comprise SDS or sarkosyl.
  • the reagent medium further comprises polyethylene glycol (PEG).
  • the methods further include contacting the biological sample with a DNase, e.g., a DNasel or DNAse II.
  • the biological sample and the array are contacted with the reagent medium for about 1 to about 60 minutes. In some instances, the biological sample and the array are contacted with the reagent medium for about 30 minutes. In some instances, the biological sample and the array are contacted with the reagent medium for less than 30 minutes. [0016] In some instances, the methods further include determining (i) all or a part of the sequence of the connected probe, or a complement thereof, and (ii) the sequence of the spatial barcode, or a complement thereof, optionally wherein the method further comprises using the determined sequence of (i) and (ii) to determine the location and abundance of the analyte in the biological sample. In some instances, the determining comprises sequencing (i) all or a part of the sequence of the connected probe, or a complement thereof, and (ii) the sequence of the spatial barcode, or a complement thereof.
  • the capture probe comprises a poly(T) sequence. In some instances, the capture probe comprises a sequence specific to the analyte. In some instances, the capture probe further comprises one or more functional domains, a unique molecular identifier (UMI), a cleavage domain, and combinations thereof.
  • UMI unique molecular identifier
  • the analyte is RNA. In some instances, the analyte is mRNA. In some instances, the analyte is DNA. In some instances, the analyte is genomic DNA.
  • the methods further include analyzing a different analyte in the biological sample.
  • the analyzing of the different analyte comprises: contacting the biological sample with a plurality of analyte capture agents, wherein an analyte capture agent of the plurality of analyte capture agents comprises an analyte binding moiety and a capture agent barcode domain, wherein the analyte binding moiety specifically binds to the different analyte, and wherein the capture agent barcode domain comprises an analyte binding moiety barcode and a capture handle sequence; and hybridizing the capture handle sequence to the capture domain.
  • the methods further include determining (i) all or part of the sequence of the capture agent barcode domain; and (ii) the sequence of the spatial barcode, or a complement thereof. In some instances, the methods further include using the determined sequence of (i), and (ii) to analyze the different analyte in the biological sample.
  • the releasing step further releases the capture agent barcode domain from the different analyte.
  • the different analyte is a protein analyte.
  • the protein analyte is an extracellular protein.
  • the protein analyte is an intracellular protein.
  • the analyte binding moiety is an antibody.
  • the analyte capture agent comprises a linker.
  • the linker is a cleavable linker.
  • the cleavable linker is a photo-cleavable linker, a UV- cleavable linker, an enzyme cleavable linker, or a chemical cleavable linker.
  • the chemical cleavable linker is a disulfide linker.
  • a method for analyzing an analyte in a biological sample mounted on a first substrate comprising: contacting the biological sample with a plurality of analyte capture agents, wherein an analyte capture agent of the plurality of analyte capture agents comprises an analyte binding moiety and a capture agent barcode domain, wherein the analyte binding moiety specifically binds to the analyte, and wherein the capture agent barcode domain comprises an analyte binding moiety barcode and an capture handle sequence; aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, wherein the array comprises a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises: (i) a spatial barcode and (ii) a capture domain; when the biological sample is aligned with at least a portion of the array,
  • the methods further include determining (i) all or a part of the capture agent barcode domain, or a complement thereof; and (ii) the sequence of the spatial barcode, or a complement thereof. In some instances, the methods further include using the determined sequence of (i) and (ii) to determine the location and abundance of the analyte in the biological sample.
  • the releasing comprises contacting the biological sample and the array with a reagent medium comprising a nuclease.
  • the coupling of the capture handle sequence to the capture domain comprises hybridization.
  • the nuclease comprises an RNase.
  • the RNase is selected from RNase A, RNase C, RNase H, and RNase I.
  • the reagent medium further comprises a permeabilization agent.
  • the releasing further comprises simultaneously permeabilizing the biological sample and releasing the capture agent barcode domain from the analyte binding moiety.
  • the permeabilization agent comprises a protease.
  • the protease is selected from trypsin, pepsin, elastase, or Proteinase K.
  • the reagent medium further comprises a detergent.
  • the detergent is selected from sodium dodecyl sulfate (SDS), sarkosyl, saponin, Triton X-100TM, or Tween- 20TM.
  • the reagent medium comprises less than 5 w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium comprises as least 5% w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium does not comprise sodium dodcyl sulfate (SDS) or sarkosyl.
  • the reagent medium further comprises PEG.
  • the biological sample and the array are contacted with the reagent medium for about 1 to about 60 minutes.
  • the biological sample is a tissue sample.
  • the tissue sample is a solid tissue sample.
  • the solid tissue sample is a tissue section.
  • the tissue sample is a fixed tissue sample.
  • the fixed tissue sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
  • the FFPE tissue is deparaffinized and decrosslinked prior to step (a).
  • the fixed tissue sample is a formalin fixed paraffin embedded cell pellet.
  • the tissue sample is a fresh frozen tissue sample.
  • the tissue sample is fixed and stained prior to step (a).
  • Some embodiments of the present disclosure are directed to methods, compositions, devices, and systems for concurrently detecting gene expression and proteins in a biological sample.
  • a way to detect proteins is by using antibodies that bind to the complementary antigens.
  • One of the main challenges of using antibodies for protein detection and/or quantification is that sometimes, the antibody data can include artifacts and/or show localized regions with disproportionately high or low protein expressions due to random background binding. Accordingly, there is a need for improved methods and systems that reduce and/or eliminate such spurious effects.
  • a method for quantifying spatial analyte data for a plurality of analytes of a first species comprises (a) exposing a plurality of analyte capture agents to a biological sample from a subject that is a member of the first species under conditions that (i) cause at least a first subset of the plurality of analyte capture agents to specifically bind to a first subset of analytes in the plurality of analytes in the biological sample, and (ii) cause at least a second subset of the plurality of analyte capture agents to non-specifically associate with the biological sample.
  • Each respective analyte capture agent in the first and second subsets of the plurality of analyte capture agents comprises a corresponding analyte binding moiety and a corresponding oligonucleotide comprising an analyte binding moiety barcode and a capture handle sequence.
  • the method comprises (b) aligning the biological sample with a first substrate comprising an array, such that at least a portion of the biological sample is aligned with the array, where the array comprises at least 1000 spatially barcoded features.
  • Each spatially barcoded feature comprises a respective capture probe plurality.
  • Each capture probe in the respective capture probe plurality comprises: (i) a respective spatial barcode, in a plurality of spatial barcodes, that spatially identifies the spatially barcoded feature on the first substrate and (ii) a capture domain sequence.
  • the method comprises (c) hybridizing, while the at least a portion of the biological sample is aligned with the array, (i) the oligonucleotide of each analyte capture agent in the first subset of the plurality of analyte capture agents, which specifically bound the first subset of analytes, to the capture domain sequence of a capture probe in a respective capture probe plurality; and (ii) the oligonucleotide of each analyte capture agent in the second subset of the plurality of analyte capture agents, which non-specifically associated with the biological sample, to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • the method comprises (d) determining, using the plurality of spatial barcodes, (i) for each respective spatially barcoded feature in the array, for each respective analyte capture agent in the first and second subset of the plurality of analyte capture agents, a respective raw count of the respective analyte capture agent whose oligonucleotide hybridized to the capture domain sequence of the capture probe in the respective spatially barcoded feature; and (ii) for each respective spatially barcoded feature in the array, for each respective analyte capture agent in the first subset of the plurality of analyte capture agents, normalizing the respective raw count of the respective analyte capture agent by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature, thereby obtaining a normalized count for each respective analyte capture agent in the first subset of the plurality of analyte capture agents for each respective
  • the analyte binding moiety of the respective analyte capture agent comprises an antibody that binds to a respective analyte of the first subset of the plurality of analytes.
  • the antibody is conjugated to the oligonucleotide of the respective analyte capture agent.
  • the corresponding capture handle sequence of the corresponding oligonucleotide comprises a nucleic acid sequence that is substantially complementary to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • the analyte binding moiety of the second analyte capture agent comprises a control antibody reactive to an antigen of a second species.
  • the second species is other than the first species.
  • the control antibody is conjugated to the oligonucleotide of the second analyte capture agent, where the capture handle sequence of the oligonucleotide of the second analyte capture agent comprises a nucleic acid sequence that is substantially complementary to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • the normalizing the respective raw count of the respective analyte capture agent by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature comprises normalizing the respective raw count of the respective analyte capture agent by the raw count of two or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature by dividing the respective raw count of the respective analyte capture agent by the sum of the raw count of the two or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature.
  • normalizing the normalizing the respective raw count of the respective analyte capture agent by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature comprises normalizing the respective raw count of the respective analyte capture agent by the raw count of two or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature by dividing the respective raw count of the respective analyte capture agent by a measure of central tendency of the raw count of the two or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature.
  • the first subset of analytes are proteins and the plurality of analytes further comprises a second subset of analytes that are nucleic acids.
  • the method further comprises contacting a first probe and a second probe to the biological sample under conditions suitable for hybridization of the first probe and the second probe to an analyte in the second subset of analytes.
  • the first probe comprises a sequence that is substantially complementary to a first portion of a sequence of the analyte.
  • the second probe comprises a sequence that is substantially complementary to a second portion of a sequence of the analyte.
  • the second or the first probe comprises a sequence that is complementary to the capture domain sequence of the capture probe in a respective capture probe plurality.
  • the method further comprises coupling the first probe and the second probe, thereby generating a connected probe, and hybridizing the connected probe to the capture domain sequence of one or more of the capture probes in one or more capture probe pluralities in the array.
  • Another aspect of the present disclosure provides a computer system comprising one or more processors, and memory.
  • One or more programs are stored in the memory and are configured to be executed by the one or more processors. It will be appreciated that this memory can be on a single computer, a network of computers, one or more virtual machines, or in a cloud computing architecture.
  • the one or more programs perform any of the disclosed methods.
  • Still another aspect of the present disclosure provides a computer readable storage medium storing one or more programs.
  • the one or more programs comprise instructions, which when executed by an electronic device with one or more processors and a memory, cause the electronic device to perform any of the disclosed methods.
  • each when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise.
  • FIG. 1 is a schematic diagram showing an example of a barcoded capture probe, as described herein.
  • FIG. 2 is a schematic illustrating a cleavable capture probe, where the cleaved capture probe can enter into a biological sample (e.g., non-permeabilized cell) and hybridize to target analytes within the cell.
  • a biological sample e.g., non-permeabilized cell
  • FIG. 3 is a schematic diagram of an exemplary multiplexed spatially-barcoded feature.
  • FIG. 4 is a schematic diagram of an exemplary analyte capture agent.
  • FIG. 5 is a schematic diagram depicting an exemplary interaction between a feature- immobilized capture probe 524 and an analyte capture agent 526.
  • FIG. 6A shows an exemplary workflow for using connected (e.g., ligated) probes to capture nucleic acid analytes.
  • FIG. 6B shows an exemplary schematic illustrating the tissue sample sandwiched between a substrate and a spatially-barcoded capture probe array, where the connected (e.g., ligated probes) are transferred to the spatially-barcoded capture probe array.
  • FIG. 7A shows an exemplary workflow for using ligated probes and analyte capture agents to capture different analytes.
  • FIG. 7B shows an exemplary schematic illustrating the tissue sample sandwiched between a substrate and a spatially-barcoded capture probe array, where the ligated probes and capture agent barcode domains are transferred to the spatially-barcoded capture probe array.
  • FIG. 8A shows an exemplary schematic illustrating the use of an RNase cleavable linker to release a capture agent barcode domain from an analyte binding moiety of an analyte capture agent.
  • FIG. 8B shows an exemplary schematic illustrating the use of a UV cleavable linker to release a capture agent barcode domain from an analyte binding moiety of an analyte capture agent.
  • FIG. 9 shows an exemplary schematic diagram depicting a sandwiching process.
  • FIG. 10 illustrates an example block diagram illustrating a computing device in accordance with some embodiments of the present disclosure.
  • FIGS. 11 A, 11B, 11C, 11D, HE, HF, 11G, HH, HI, HJ, 11K, and HL collectively illustrate a method for quantifying spatial analyte data for a plurality of analytes of a first species, in accordance with some embodiments.
  • FIGS. 12A and 12B collectively illustrate a list of antibodies that are used in accordance with some embodiments of the present disclosure.
  • FIG. 13 illustrates a table of analyte capture agents in accordance with some embodiments of the present disclosure.
  • FIG. 14 illustrates an image where antibody data of a biological sample is spatially overlaid on a histological image 1404 of the same biological sample.
  • FIGS. 15A and 15B are exemplary data showing the spatial distribution of antibodies on the same tissue section before and after normalization in accordance with some embodiments of the present disclosure.
  • FIG. 16 illustrates an exemplary normalization pathway that utilizes the unique molecular identifier (UMI) of four control antibodies to control for non-specific biological expression in the data, in accordance with some embodiments of the present disclosure.
  • UMI unique molecular identifier
  • FIGS. 17A and 17B illustrate cross-correlation data of analyte capture agents (e.g., oligonucleotide-conjugated antibodies) before and after normalization, respectively, in accordance with some embodiments of the present disclosure.
  • analyte capture agents e.g., oligonucleotide-conjugated antibodies
  • FIG. 18 illustrates that the normalization process in the present disclosure aids the detection of biological structures and spatial analysis of analytes in accordance with some embodiments of the present disclosure.
  • FIGS. 19A, 19B, and 19C collectively illustrate an application quantifying spatial analyte data for a plurality of analytes of a first species, in accordance with some embodiments of the present disclosure.
  • Spatial analysis methodologies, systems, and compositions described herein can provide a vast amount of analyte and/or expression data for a variety of analytes within a biological sample at high resolution, while retaining native spatial context.
  • Spatial analysis methods and compositions can include, e.g., the use of a capture probe including a spatial barcode (e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample (e.g., mammalian cell or a mammalian tissue sample) and a capture domain that is capable of binding to an analyte (e.g., a nucleic acid) produced by and/or present in a cell.
  • a spatial barcode e.g., a nucleic acid sequence that provides information as to the location or position of an analyte within a cell or a tissue sample
  • a capture domain that is capable of binding to an analyte (e.g.
  • Spatial analysis methods and compositions can also include the use of a capture probe having a capture domain that captures an intermediate agent for indirect detection of an analyte (e.g., protein).
  • the intermediate agent can include a nucleic acid sequence (e.g., a barcode) associated with the intermediate agent. Detection of the intermediate agent is therefore indicative of the analyte in the cell or tissue sample.
  • a “barcode” is a label, or identifier, that conveys or is capable of conveying information (e.g., information about an analyte in a sample, a bead, and/or a capture probe).
  • a barcode can be part of an analyte, or independent of an analyte.
  • a barcode can be attached to an analyte.
  • a particular barcode can be unique relative to other barcodes.
  • an “analyte” can include any biological substance, structure, moiety, or component to be analyzed.
  • target can similarly refer to an analyte of interest.
  • Analytes can be broadly classified into one of two groups: nucleic acid analytes, and non-nucleic acid analytes.
  • non-nucleic acid analytes include, but are not limited to, lipids, carbohydrates, peptides, proteins, glycoproteins (N-linked or O-linked), lipoproteins, phosphoproteins, specific phosphorylated or acetylated variants of proteins, amidation variants of proteins, hydroxylation variants of proteins, methylation variants of proteins, ubiquitylation variants of proteins, sulfation variants of proteins, viral proteins (e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.), extracellular and intracellular proteins, antibodies, and antigen binding fragments.
  • viral proteins e.g., viral capsid, viral envelope, viral coat, viral accessory, viral glycoproteins, viral spike, etc.
  • nucleic acid analytes include, but are not limited to, DNA (e.g., genomic DNA, cDNA) and RNA, including coding and noncoding RNA (e.g., mRNA, rRNA, tRNA, ncRNA).
  • DNA e.g., genomic DNA, cDNA
  • RNA including coding and noncoding RNA (e.g., mRNA, rRNA, tRNA, ncRNA).
  • the analyte(s) can be localized to subcellular location(s), including, for example, organelles, e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc.
  • organelles e.g., mitochondria, Golgi apparatus, endoplasmic reticulum, chloroplasts, endocytic vesicles, exocytic vesicles, vacuoles, lysosomes, etc.
  • analyte(s) can be peptides or proteins, including without limitation antibodies and enzymes. Additional examples of analytes can be found in Section (I)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • an analyte can be detected indirectly, such as through detection of an intermediate agent, for example, a connected probe (e.g., a ligation product) or an analyte capture agent (e.g., an oligonucleotide- conjugated antibody), such as those described herein.
  • an intermediate agent for example, a connected probe (e.g., a ligation product) or an analyte capture agent (e.g., an oligonucleotide- conjugated antibody), such as those described herein.
  • a “biological sample” is typically obtained from the subject for analysis using any of a variety of techniques including, but not limited to, biopsy, surgery, and laser capture microscopy (LCM), and generally includes cells and/or other biological material from the subject.
  • the biological sample is a tissue sample.
  • the biological sample e.g., tissue sample
  • TMA tissue microarray
  • a tissue microarray contains multiple representative tissue samples - which can be from different tissues or organisms - assembled on a single histologic slide. The TMA can therefore allow for high throughput analysis of multiple specimens at the same time.
  • Tissue microarrays are paraffin blocks produced by extracting cylindrical tissue cores from different paraffin donor blocks and re-embedding these into a single recipient (microarray) block at defined array coordinates.
  • the biological sample can be any suitable biological sample described herein or known in the art.
  • the biological sample is a tissue.
  • the tissue sample is a solid tissue sample.
  • a biological sample can be a tissue section.
  • the tissue sample can be obtained from any suitable location in a tissue or organ of a subject, e.g., a human subject.
  • the tissue sample is a mouse sample.
  • the tissue sample is a human sample.
  • the tissue sample can be derived from skin, brain, breast, lung, liver, kidney, prostate, tonsil, thymus, testes, bone, lymph node, ovary, eye, heart, or spleen.
  • the tissue sample is flash-frozen and sectioned.
  • the biological sample e.g., the tissue
  • the biological sample is flash-frozen using nitrogen (e.g., liquid nitrogen), isopentane, or hexane before sectioning.
  • the biological sample e.g., the tissue
  • a matrix e.g., optimal cutting temperature (OCT) compound to facilitate sectioning.
  • OCT compound is a formulation of clear, water-soluble glycols and resins, providing a solid matrix to encapsulate biological (e.g., tissue) specimens.
  • the sectioning is performed using cryosectioning.
  • the methods further comprise a thawing step, after the cryosectioning.
  • the biological sample e.g., the tissue sample
  • a fixative including alcohol for example methanol.
  • alcohol for example methanol.
  • acetone instead of methanol, acetone, or an acetone-methanol mixture can be used.
  • the fixation is performed after sectioning.
  • the biological sample is not fixed with paraformaldehyde (PF A).
  • PF A paraformaldehyde
  • the biological sample e.g., the tissue sample
  • the fixative is preferably an aldehyde fixative, such as paraformaldehyde (PF A) or formalin.
  • the fixative induces crosslinks within the biological sample.
  • the biological sample is dehydrated via sucrose gradient.
  • the fixed biological sample is treated with a sucrose gradient and then embedded in a matrix e.g., OCT compound.
  • the fixed biological sample is not treated with a sucrose gradient, but rather is embedded in a matrix e.g., OCT compound after fixation.
  • a fixed frozen tissue sample when a fixed frozen tissue sample is treated with a sucrose gradient, it can be rehydrated with an ethanol gradient.
  • the PFA or formalin fixed biological sample which can be optionally dehydrated via sucrose gradient and/or embedded in OCT compound, is then frozen e.g., for storage or shipment.
  • the biological sample can be fixed using PAXgene.
  • the biological sample can be fixed using PAXgene in addition, or alternatively to, a fixative disclosed herein or known in the art (e.g., alcohol, acetone, acetone-alcohol, formalin, paraformaldehyde).
  • PAXgene is a non-cross-linking mixture of different alcohols, acid and a soluble organic compound that preserves morphology and bio-molecules. It is a two-reagent fixative system in which tissue is firstly fixed in a solution containing methanol and acetic acid then stabilized in a solution containing ethanol. See, Ergin B. et cd.. J Proteome Res.
  • the biological sample can be from a mammal. In some instances, the biological sample is from a human, mouse, or rat.
  • the biological sample can be obtained from non-mammalian organisms (e.g., a plants, an insect, an arachnid, a nematode (e.g., Caenorhabditis elegans . a fungi, an amphibian, or a fish (e.g., zebrafish)).
  • Biological samples can include one or more diseased cells.
  • a diseased cell can have altered metabolic properties, gene expression, protein expression, and/or morphologic features.
  • diseases include inflammatory disorders, metabolic disorders, nervous system disorders, and cancer.
  • Cancer cells can be derived from solid tumors, hematological malignancies, cell lines, or obtained as circulating tumor cells.
  • a biological sample can be a fixed and/or stained biological sample (e.g., a fixed and/or stained tissue section).
  • stains include histological stains (e.g., hematoxylin and/or eosin) and immunological stains (e.g., fluorescent stains).
  • a biological sample e.g., a fixed and/or stained biological sample
  • Biological samples are also described in Section (I)(d) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • a biological sample is permeabilized with one or more permeabilization reagents.
  • permeabilization of a biological sample can facilitate analyte capture.
  • Exemplary permeabilization agents and conditions are described in Section (I)(d)(ii)(13) or the Exemplary Embodiments Section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Array-based spatial analysis methods involve the transfer of one or more analytes from a biological sample to an array of features on a substrate, where each feature is associated with a unique spatial location on the array. Subsequent analysis of the transferred analytes includes determining the identity of the analytes and the spatial location of the analytes within the biological sample. The spatial location of an analyte within the biological sample is determined based on the feature to which the analyte is bound (e.g., directly or indirectly) on the array, and the feature’s relative spatial location within the array.
  • a “capture probe” refers to any molecule capable of capturing (directly or indirectly) and/or labelling an analyte (e.g., an analyte of interest) in a biological sample.
  • the capture probe is a nucleic acid or a polypeptide.
  • the capture probe includes a barcode (e.g., a spatial barcode and/or a unique molecular identifier (UMI)) and a capture domain).
  • UMI unique molecular identifier
  • a capture probe can include a cleavage domain and/or a functional domain (e.g., a primer-binding site, such as for next-generation sequencing (NGS)).
  • NGS next-generation sequencing
  • the capture domain is designed to detect one or more specific analytes of interest.
  • a capture domain can be designed so that it comprises a sequence that is complementary or substantially complementary to one analyte of interest.
  • the capture domain can be designed so that it comprises a sequence that is complementary or substantially complementary to a conserved region of multiple related analytes.
  • the multiple related analytes are analytes that function in the same or similar cellular pathways or that have conserved homology and/or function.
  • the design of the capture probe can be determined based on the intent of the user and can be any sequence that can be used to detect an analyte of interest.
  • the capture domain sequence can therefore be random, semi-random, defined or combinations thereof, depending on the target analyte(s) of interest.
  • FIG. 1 is a schematic diagram showing an exemplary capture probe, as described herein.
  • the capture probe 102 is optionally coupled to a feature 101 by a cleavage domain 103, such as a disulfide linker.
  • the capture probe can include a functional sequence 104 that are useful for subsequent processing.
  • the functional sequence 104 can include all or a part of sequencer specific flow cell attachment sequence (e.g., a P5 or P7 sequence), all or a part of a sequencing primer sequence, e.g., a R1 primer binding site, a R2 primer binding site), or combinations thereof.
  • the capture probe can also include a spatial barcode 105.
  • the capture probe can also include a unique molecular identifier (UMI) sequence 106.
  • UMI unique molecular identifier
  • FIG. 1 shows the spatial barcode 105 as being located upstream (5’) of UMI sequence 106
  • capture probes where UMI sequence 106 is located upstream (5’) of the spatial barcode 105 is also suitable for use in any of the methods described herein.
  • the capture probe can also include a capture domain 107 to facilitate capture of a target analyte.
  • the capture probe comprises one or more additional functional sequences that can be located, for example between the spatial barcode 105 and the UMI sequence 106, between the UMI sequence 106 and the capture domain 107, or following the capture domain 107.
  • the capture domain can have a sequence complementary to a sequence of a nucleic acid analyte.
  • the capture domain can have a sequence complementary to a connected probe described herein.
  • the capture domain can have a sequence complementary to a capture handle sequence present in an analyte capture agent.
  • the capture domain can have a sequence complementary to a splint oligonucleotide.
  • Such splint oligonucleotide in addition to having a sequence complementary to a capture domain of a capture probe, can have a sequence of a nucleic acid analyte, a sequence complementary to a portion of a connected probe described herein, and/or a capture handle sequence described herein.
  • the functional sequences can generally be selected for compatibility with any of a variety of different sequencing systems, e.g., Ion Torrent Proton or PGM, Illumina sequencing instruments, PacBio, Oxford Nanopore, etc., and the requirements thereof.
  • functional sequences can be selected for compatibility with non-commercialized sequencing systems. Examples of such sequencing systems and techniques, for which suitable functional sequences can be used, include (but are not limited to) Ion Torrent Proton or PGM sequencing, Illumina sequencing, PacBio SMRT sequencing, and Oxford Nanopore sequencing.
  • functional sequences can be selected for compatibility with other sequencing systems, including non-commercialized sequencing systems.
  • the spatial barcode 105 and functional sequences 104 is common to all of the probes attached to a given feature.
  • the UMI sequence 106 of a capture probe attached to a given feature is different from the UMI sequence of a different capture probe attached to the given feature.
  • FIG. 2 is a schematic illustrating a cleavable capture probe, where the cleaved capture probe can enter into a non-permeabilized cell and bind to analytes within the sample (e.g., cell).
  • the capture probe 201 contains a cleavage domain 202, a cell penetrating peptide 203, a reporter molecule 204, and a disulfide bond (-S-S-).
  • 205 represents all other parts of a capture probe, for example a spatial barcode and a capture domain.
  • FIG. 3 is a schematic diagram of an exemplary multiplexed spatially-barcoded feature.
  • the feature 301 can be coupled to spatially-barcoded capture probes, where the spatially-barcoded probes of a particular feature can possess the same spatial barcode, but have different capture domains designed to associate the spatial barcode of the feature with more than one target analyte.
  • a feature may be coupled to four different types of spatially- barcoded capture probes, each type of spatially-barcoded capture probe possessing the spatial barcode 302.
  • One type of capture probe associated with the feature includes the spatial barcode 302 in combination with a poly(T) capture domain 303, designed to capture mRNA target analytes.
  • a second type of capture probe associated with the feature includes the spatial barcode 302 in combination with a random N-mer capture domain 304 for gDNA analysis.
  • a third type of capture probe associated with the feature includes the spatial barcode 302 in combination with a capture domain complementary to a capture handle sequence of an analyte capture agent of interest 305.
  • a fourth type of capture probe associated with the feature includes the spatial barcode 302 in combination with a capture domain that can specifically bind a nucleic acid molecule 306 that can function in a CRISPR assay (e.g., CRISPR/Cas9). While only four different capture probe-barcoded constructs are shown in FIG.
  • capture-probe barcoded constructs can be tailored for analyses of any given analyte associated with a nucleic acid and capable of binding with such a construct.
  • the schemes shown in FIG. 3 can also be used for concurrent analysis of other analytes disclosed herein, including, but not limited to: (a) mRNA, a lineage tracing construct, cell surface or intracellular proteins and metabolites, and gDNA; (b) mRNA, accessible chromatin (e.g., ATAC-seq, DNase-seq, and/or MNase-seq) cell surface or intracellular proteins and metabolites, and a perturbation agent (e.g., a CRISPR crRNA/sgRNA, TALEN, zinc finger nuclease, and/or antisense oligonucleotide as described herein); (c) mRNA, cell surface or intracellular proteins and/or metabolites, a barcoded labelling agent (e.g., the MHC multimers described here
  • a perturbation agent can be a small molecule, an antibody, a drug, an aptamer, a miRNA, a physical environmental e.g., temperature change), or any other known perturbation agents. See, e.g., Section (II)(b) e.g., subsections (i)- (vi)) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Generation of capture probes can be achieved by any appropriate method, including those described in Section (II)(d)(ii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • more than one analyte type e.g., nucleic acids and proteins) from a biological sample can be detected e.g., simultaneously or sequentially) using any appropriate multiplexing technique, such as those described in Section (IV) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • an “analyte capture agent” refers to an agent that interacts with an analyte e.g., an analyte in a biological sample) and with a capture probe e.g., a capture probe attached to a substrate or a feature) to identify the analyte.
  • the analyte capture agent includes: (i) an analyte binding moiety e.g., that binds to an analyte), for example, an antibody or antigen-binding fragment thereof; (ii) analyte binding moiety barcode; and (iii) a capture handle sequence.
  • analyte binding moiety barcode refers to a barcode that is associated with or otherwise identifies the analyte binding moiety.
  • the term “analyte capture sequence” or “capture handle sequence” refers to a region or moiety configured to hybridize to, bind to, couple to, or otherwise interact with a capture domain of a capture probe.
  • a capture handle sequence is complementary to a capture domain of a capture probe.
  • an analyte binding moiety barcode (or portion thereof) may be able to be removed (e.g., cleaved) from the analyte capture agent.
  • antibody refers to an immunoglobulin molecule which specifically binds with an antigen.
  • Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact immunoglobulins. Unless specifically noted otherwise, use of the term “antibody” or “antibodies” may specifically include “antibody fragment” and “antibody fragments” which include any form of an antibody other than the full-length form.
  • a disclosed antibody may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)2, single chain Fv (scFv), diabodies, triabodies, tetrabodies, bifunctional hybrid antibodies, CDR1, CDR2, CDR3, combinations of CDRs, variable regions, framework regions, constant regions, heavy chains, light chains, alternative scaffold non-antibody molecules, and bispecific antibodies, and humanized antibodies.
  • FIG. 4 is a schematic diagram of an exemplary analyte capture agent 402 comprised of an analyte-binding moiety 404 and an oligonucleotide (also referred to herein as analytebinding moiety barcode domain) 408.
  • the exemplary analyte-binding moiety 404 is a molecule capable of binding to an analyte 406 and the oligonucleotide is capable of interacting with a spatially-barcoded capture probe.
  • the analyte binding moiety can bind to the analyte 406 with high affinity and/or with high specificity.
  • the analyte capture agent can include an oligonucleotide 408, which can include a nucleotide sequence which can hybridize to at least a portion or an entirety of a capture domain of a capture probe.
  • the oligonucleotide 408 can comprise an analyte binding moiety barcode and a capture handle sequence described herein.
  • the analyte binding moiety 404 can include a polypeptide and/or an aptamer.
  • the analyte-binding moiety 404 can include an antibody or antibody fragment (e.g., an antigen-binding fragment).
  • FIG. 5 is a schematic diagram depicting an exemplary interaction between a feature- immobilized capture probe 524 and an analyte capture agent 526.
  • the feature-immobilized capture probe 524 can include a spatial barcode 508 as well as functional sequences 506 and UMI 510, as described elsewhere herein.
  • the capture probe can also include a capture domain 512 that is capable of binding to an analyte capture agent 526.
  • the analyte capture agent 526 can include a functional sequence 518, analyte binding moiety barcode 516, and a capture handle sequence 514 that is capable of binding to the capture domain 512 of the capture probe 524.
  • the analyte capture agent can also include a linker 520 that allows the capture agent barcode domain 516 to couple to the analyte binding moiety 522.
  • streptavidin cell tags can be utilized in an array -based system to produce a spatially-barcoded cell or cellular contents.
  • peptide-bound major histocompatibility complex MHC
  • P2m biotin
  • streptavidin moiety comprises multiple pMHC moieties.
  • Each of these moieties can bind to a TCR such that the streptavidin binds to a target T- cell via multiple MCH/TCR binding interactions. Multiple interactions synergize and can substantially improve binding affinity. Such improved affinity can improve labelling of T-cells and also reduce the likelihood that labels will dissociate from T-cell surfaces.
  • a capture agent barcode domain can be modified with streptavidin and contacted with multiple molecules of biotinylated MHC such that the biotinylated MHC molecules are coupled with the streptavidin conjugated capture agent barcode domain.
  • the result is a barcoded MHC multimer complex.
  • the capture agent barcode domain sequence can identify the MHC as its associated label and also includes optional functional sequences such as sequences for hybridization with other oligonucleotides.
  • one example oligonucleotide is a capture probe that comprises a complementary sequence (e.g., rGrGrG corresponding to C C C), a barcode sequence and other functional sequences, such as, for example, a UMI, an adapter sequence (e.g., comprising a sequencing primer sequence (e.g., R1 or a partial R1 (“pRl”), R2), a flow cell attachment sequence (e.g., P5 or P7 or partial sequences thereof)), etc.
  • capture probe may at first be associated with a feature (e.g., a gel bead) and released from the feature.
  • capture probe can hybridize with a capture agent barcode domain of the MHC-oligonucleotide complex.
  • the hybridized oligonucleotides (Spacer C C C and Spacer rGrGrG) can then be extended in primer extension reactions such that constructs comprising sequences that correspond to each of the two spatial barcode sequences (the spatial barcode associated with the capture probe, and the barcode associated with the MHC-oligonucleotide complex) are generated.
  • one or both of these corresponding sequences may be a complement of the original sequence in capture probe or capture agent barcode domain.
  • the capture probe and the capture agent barcode domain are ligated together.
  • the resulting constructs can be optionally further processed (e.g., to add any additional sequences and/or for clean-up) and subjected to sequencing.
  • a sequence derived from the capture probe spatial barcode sequence may be used to identify a feature and the sequence derived from spatial barcode sequence on the capture agent barcode domain may be used to identify the particular peptide MHC complex bound on the surface of the cell (e.g., when using MHC -peptide libraries for screening immune cells or immune cell populations).
  • a spatial barcode with one or more neighboring cells, such that the spatial barcode identifies the one or more cells, and/or contents of the one or more cells, as associated with a particular spatial location.
  • One method is to promote analytes or analyte proxies (e.g., intermediate agents) out of a cell and towards a spatially- barcoded array (e.g., including spatially-barcoded capture probes).
  • Another method is to cleave spatially-barcoded capture probes from an array and promote the spatially-barcoded capture probes towards and/or into or onto the biological sample.
  • capture probes may be configured to prime, replicate, and consequently yield optionally barcoded extension products from a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a connected probe (e.g., a ligation product) or an analyte capture agent), or a portion thereof), or derivatives thereof (see, e.g., Section (II)(b)(vii) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663 regarding extended capture probes).
  • a template e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g., a connected probe (e.g., a ligation product) or an analyte capture agent), or a portion thereof
  • a template e.g., a DNA or RNA template, such as an analyte or an intermediate agent (e.g.,
  • capture probes may be configured to form a connected probe (e.g., a ligation product) with a template (e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof), thereby creating ligations products that serve as proxies for a template.
  • a connected probe e.g., a ligation product
  • a template e.g., a DNA or RNA template, such as an analyte or an intermediate agent, or portion thereof
  • an “extended capture probe” refers to a capture probe having additional nucleotides added to the terminus (e.g., 3’ or 5’ end) of the capture probe thereby extending the overall length of the capture probe.
  • an “extended 3’ end” indicates additional nucleotides were added to the most 3’ nucleotide of the capture probe to extend the length of the capture probe, for example, by polymerization reactions used to extend nucleic acid molecules including templated polymerization catalyzed by a polymerase (e.g., a DNA polymerase or a reverse transcriptase).
  • a polymerase e.g., a DNA polymerase or a reverse transcriptase
  • extending the capture probe includes adding to a 3’ end of a capture probe a nucleic acid sequence that is complementary to a nucleic acid sequence of an analyte or intermediate agent specifically bound to the capture domain of the capture probe.
  • the capture probe is extended using reverse transcription.
  • the capture probe is extended using one or more DNA polymerases. The extended capture probes include the sequence of the capture probe and the sequence of the spatial barcode of the capture probe.
  • extended capture probes are amplified (e.g., in bulk solution or on the array) to yield quantities that are sufficient for downstream analysis, e.g., via DNA sequencing.
  • extended capture probes e.g., DNA molecules
  • act as templates for an amplification reaction e.g., a polymerase chain reaction.
  • Analysis of captured analytes (and/or intermediate agents or portions thereof), for example, including sample removal, extension of capture probes, sequencing (e.g., of a cleaved extended capture probe and/or a cDNA molecule complementary to an extended capture probe), sequencing on the array (e.g., using, for example, in situ hybridization or in situ ligation approaches), temporal analysis, and/or proximity capture is described in Section (II)(g) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Some quality control measures are described in Section (II)(h) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • Spatial information can provide information of biological and/or medical importance.
  • the methods and compositions described herein can allow for: identification of one or more biomarkers (e.g., diagnostic, prognostic, and/or for determination of efficacy of a treatment) of a disease or disorder; identification of a candidate drug target for treatment of a disease or disorder; identification (e.g., diagnosis) of a subject as having a disease or disorder; identification of stage and/or prognosis of a disease or disorder in a subject; identification of a subject as having an increased likelihood of developing a disease or disorder; monitoring of progression of a disease or disorder in a subject; determination of efficacy of a treatment of a disease or disorder in a subject; identification of a patient subpopulation for which a treatment is effective for a disease or disorder; modification of a treatment of a subject with a disease or disorder; selection of a subject for participation in a clinical trial; and/or selection of a treatment for a subject with a disease or disorder.
  • Spatial information can provide information of biological importance.
  • the methods and compositions described herein can allow for: identification of transcriptome and/or proteome expression profiles (e.g., in healthy and/or diseased tissue); identification of multiple analyte types in close proximity (e.g., nearest neighbor analysis); determination of up- and/or down-regulated genes and/or proteins in diseased tissue; characterization of tumor microenvironments; characterization of tumor immune responses; characterization of cells types and their co-localization in tissue; and identification of genetic variants within tissues (e.g., based on gene and/or protein expression profiles associated with specific disease or disorder biomarkers).
  • a substrate functions as a support for direct or indirect attachment of capture probes to features of the array.
  • a “feature” is an entity that acts as a support or repository for various molecular entities used in spatial analysis.
  • some or all of the features in an array are functionalized for analyte capture.
  • Exemplary substrates are described in Section (II)(c) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • analytes and/or intermediate agents can be captured when contacting a biological sample with a substrate including capture probes (e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells) comprising capture probes).
  • capture probes e.g., a substrate with capture probes embedded, spotted, printed, fabricated on the substrate, or a substrate with features (e.g., beads, wells) comprising capture probes.
  • contact contacted
  • contacting a biological sample with a substrate refers to any contact (e.g., direct or indirect) such that capture probes can interact (e.g., bind covalently or non-covalently (e.g., hybridize)) with analytes from the biological sample.
  • Capture can be achieved actively (e.g., using electrophoresis) or passively (e.g., using diffusion). Analyte capture is further described in Section (II)(e) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • spatial analysis can be performed by attaching and/or introducing a molecule (e.g., a peptide, a lipid, or a nucleic acid molecule) having a barcode (e.g., a spatial barcode) to a biological sample (e.g., to a cell in a biological sample).
  • a plurality of molecules e.g., a plurality of nucleic acid molecules
  • a plurality of barcodes e.g., a plurality of spatial barcodes
  • a biological sample e.g., to a plurality of cells in a biological sample
  • the biological sample after attaching and/or introducing a molecule having a barcode to a biological sample, the biological sample can be physically separated (e.g., dissociated) into single cells or cell groups for analysis.
  • Some such methods of spatial analysis are described in Section (III) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663.
  • spatial analysis can be performed by detecting multiple oligonucleotides that hybridize to an analyte.
  • spatial analysis can be performed using RNA-templated ligation (RTL). Methods of RTL have been described previously. See, e.g., Credle etal., Nucleic Acids Res.
  • RTL includes hybridization of two oligonucleotides to adjacent sequences on an analyte (e.g., an RNA molecule, such as an mRNA molecule).
  • the oligonucleotides are DNA molecules.
  • one of the oligonucleotides includes at least two ribonucleic acid bases at the 3’ end and/or the other oligonucleotide includes a phosphorylated nucleotide at the 5’ end.
  • one of the two oligonucleotides includes a capture domain (e.g., a poly(A) sequence, a non-homopolymeric sequence).
  • a ligase e.g., SplintR ligase
  • a connected probe e.g., a ligation product
  • the two oligonucleotides hybridize to sequences that are not adjacent to one another. For example, hybridization of the two oligonucleotides creates a gap between the hybridized oligonucleotides.
  • a polymerase e.g., a DNA polymerase
  • the connected probe e.g., a ligation product
  • the connected probe is released from the analyte.
  • the connected probe e.g., a ligation product
  • an endonuclease e.g., RNase A, RNase C, RNase H, or RNase I.
  • the released connected probe can then be captured by capture probes (e.g., instead of direct capture of an analyte) on an array, optionally amplified, and sequenced, thus determining the location and optionally the abundance of the analyte in the biological sample.
  • sequence information for a spatial barcode associated with an analyte is obtained, and the sequence information can be used to provide information about the spatial distribution of the analyte in the biological sample.
  • Various methods can be used to obtain the spatial information.
  • specific capture probes and the analytes they capture are associated with specific locations in an array of features on a substrate.
  • specific spatial barcodes can be associated with specific array locations prior to array fabrication, and the sequences of the spatial barcodes can be stored (e.g., in a database) along with specific array location information, so that each spatial barcode uniquely maps to a particular array location.
  • specific spatial barcodes can be deposited at predetermined locations in an array of features during fabrication such that at each location, only one type of spatial barcode is present so that spatial barcodes are uniquely associated with a single feature of the array.
  • the arrays can be decoded using any of the methods described herein so that spatial barcodes are uniquely associated with array feature locations, and this mapping can be stored as described above.
  • each array feature location represents a position relative to a coordinate reference point (e.g., an array location, a fiducial marker) for the array. Accordingly, each feature location has an “address” or location in the coordinate space of the array.
  • Some exemplary spatial analysis workflows are described in the Exemplary Embodiments section of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See, for example, the Exemplary embodiment starting with “In some non-limiting examples of the workflows described herein, the sample can be immersed. . .” of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663. See also, e.g., the Visium Spatial Gene Expression Reagent Kits User Guide (e.g., Rev C, dated June 2020), and/or the Visium Spatial Tissue Optimization Reagent Kits User Guide (e.g., Rev C, dated July 2020).
  • the Visium Spatial Gene Expression Reagent Kits User Guide e.g., Rev C, dated June 2020
  • the Visium Spatial Tissue Optimization Reagent Kits User Guide e.g., Rev C, dated July 2020.
  • spatial analysis can be performed using dedicated hardware and/or software, such as any of the systems described in Sections (II)(e)(ii) and/or (V) of WO 2020/176788 and/or U.S. Patent Application Publication No. 2020/0277663, or any of one or more of the devices or methods described in Sections Control Slide for Imaging, Methods of Using Control Slides and Substrates for, Systems of Using Control Slides and Substrates for Imaging, and/or Sample and Array Alignment Devices and Methods, Informational labels of WO 2020/123320.
  • Suitable systems for performing spatial analysis can include components such as a chamber (e.g., a flow cell or sealable, fluid-tight chamber) for containing a biological sample.
  • the biological sample can be mounted for example, in a biological sample holder.
  • One or more fluid chambers can be connected to the chamber and/or the sample holder via fluid conduits, and fluids can be delivered into the chamber and/or sample holder via fluidic pumps, vacuum sources, or other devices coupled to the fluid conduits that create a pressure gradient to drive fluid flow.
  • One or more valves can also be connected to fluid conduits to regulate the flow of reagents from reservoirs to the chamber and/or sample holder.
  • the systems can optionally include a control unit that includes one or more electronic processors, an input interface, an output interface (such as a display), and a storage unit (e.g., a solid state storage medium such as, but not limited to, a magnetic, optical, or other solid state, persistent, writeable and/or re-writeable storage medium).
  • the control unit can optionally be connected to one or more remote devices via a network.
  • the control unit (and components thereof) can generally perform any of the steps and functions described herein. Where the system is connected to a remote device, the remote device (or devices) can perform any of the steps or features described herein.
  • the systems can optionally include one or more detectors (e.g., CCD, CMOS) used to capture images.
  • the systems can also optionally include one or more light sources (e.g., LED-based, diode-based, lasers) for illuminating a sample, a substrate with features, analytes from a biological sample captured on a substrate, and various control and calibration media.
  • one or more light sources e.g., LED-based, diode-based, lasers
  • the systems can optionally include software instructions encoded and/or implemented in one or more of tangible storage media and hardware components such as application specific integrated circuits.
  • the software instructions when executed by a control unit (and in particular, an electronic processor) or an integrated circuit, can cause the control unit, integrated circuit, or other component executing the software instructions to perform any of the method steps or functions described herein.
  • the systems described herein can detect (e.g., register an image) the biological sample on the array.
  • Exemplary methods to detect the biological sample on an array are described in PCT Application No. 2020/061064 and/or U.S. Patent Publication No. US2021/0155982.
  • the biological sample Prior to transferring analytes from the biological sample to the array of features on the substrate, the biological sample can be aligned with the array. Alignment of a biological sample and an array of features including capture probes can facilitate spatial analysis, which can be used to detect differences in analyte presence and/or level within different positions in the biological sample, for example, to generate a three-dimensional map of the analyte presence and/or level. Exemplary methods to generate a two- and/or three-dimensional map of the analyte presence and/or level are described in PCT Application No. 2020/053655 and spatial analysis methods are generally described in WO 2020/061108 and/or U.S. Patent Publication No. US2021/0155982.
  • a map of analyte presence and/or level can be aligned to an image of a biological sample using one or more fiducial markers, e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in the Substrate Attributes Section, Control Slide for Imaging Section of WO 2020/123320, PCT Application No. 2020/061066, and/or U.S. Patent Application Publication No. 2021/0158522.
  • fiducial markers e.g., objects placed in the field of view of an imaging system which appear in the image produced, as described in the Substrate Attributes Section, Control Slide for Imaging Section of WO 2020/123320, PCT Application No. 2020/061066, and/or U.S. Patent Application Publication No. 2021/0158522.
  • Fiducial markers can be used as a point of reference or measurement scale for alignment (e.g., to align a sample and an array, to align two substrates, to determine a location of a sample or array on a substrate relative to a fiducial marker) and/or for quantitative measurements of sizes and/or distances.
  • the methods include aligning (i.e., sandwiching) a first substrate having the biological sample with a second substrate that includes a plurality of capture probes, thereby “sandwiching” the biological sample between the two substrates.
  • aligning i.e., sandwiching
  • the substrate having a plurality of probes Upon interaction of the biological sample with the substrate having a plurality of probes (in either instance), the location and abundance of a nucleic acid or protein analyte in a biological sample can be determined, as provided herein.
  • an analyte derived molecule includes, without limitation, a connected probe (e.g., a ligation product) from an RNA-templated ligation (RTL) assay, a product of reverse transcription (e.g., an extended capture probe), and an analyte binding moiety barcode (e.g., a binding moiety barcode that identifies that analyte binding moiety (e.g., an antibody)).
  • RTL RNA-templated ligation
  • an extended capture probe e.g., an extended capture probe
  • an analyte binding moiety barcode e.g., a binding moiety barcode that identifies that analyte binding moiety (e.g., an antibody)
  • the analyte or analyte derived molecules comprise RNA and/or DNA.
  • the analyte or analyte derived molecules comprise one or more proteins.
  • the methods, devices, compositions, and systems disclosed herein provide efficient release of an analyte or analyte derived molecule from a biological sample so that it can be easily captured or detected using methods disclosed herein.
  • the methods, devices, compositions, and systems disclosed herein allow for detection of analytes or analyte derived molecules from different biological samples using a single array comprising a plurality of capture probes.
  • the methods, devices, compositions, and systems allow for serial capture of analytes or analyte derived molecules from multiple samples. The analytes or analyte derived molecules can then be demultiplexed using biological-sample-specific index sequences to identify it biological sample origin.
  • the biological sample as used herein can be any suitable biological sample described herein or known in the art.
  • the biological sample is a tissue.
  • the tissue sample is a solid tissue sample.
  • the biological sample is a tissue section.
  • the tissue is flash-frozen and sectioned. Any suitable methods described herein or known in the art can be used to flash-freeze and section the tissue sample.
  • the biological sample, e.g., the tissue is flash-frozen using liquid nitrogen before sectioning.
  • the sectioning is performed using cryosectioning.
  • the methods further comprise a thawing step, after the cryosectioning.
  • the biological sample e.g., the tissue sample is fixed, for example in methanol, acetone, PFA or is formalin-fixed and paraffin-embedded (FFPE).
  • the biological sample comprises intact cells.
  • the biological sample is a cell pellet, e.g., a fixed cell pellet, e.g., an FFPE cell pellet. FFPE samples are used in some instances in the RTL methods disclosed herein.
  • RNA integrity of fixed (e.g., FFPE) samples can be lower than a fresh sample, thereby making it more difficult to capture RNA directly, e.g., by capture of a common sequence such as a poly(A) tail of an mRNA molecule.
  • RTL probe oligonucleotides that hybridize to RNA target sequences in the transcriptome, one can avoid a requirement for RNA analytes to have both a poly(A) tail and target sequences intact.
  • RTL probes can be utilized to beneficially improve capture and spatial analysis of fixed samples.
  • the biological sample e.g., tissue sample
  • the biological sample can be stained, and imaged prior, during, and/or after each step of the methods described herein. Any of the methods described herein or known in the art can be used to stain and/or image the biological sample.
  • the imaging occurs prior to deaminating the sample.
  • the biological sample is stained using an H&E staining method.
  • the tissue sample is stained and imaged for about 10 minutes to about 2 hours (or any of the subranges of this range described herein). Additional time may be needed for staining and imaging of different types of biological samples.
  • the tissue sample can be obtained from any suitable location in a tissue or organ of a subject, e.g., a human subject.
  • the sample is a human sample.
  • the sample is a human breast tissue sample.
  • the sample is a human brain tissue sample.
  • the sample is an embryo sample.
  • the embryo sample can be a non-human embryo sample.
  • the sample is a mouse embryo sample.
  • the biological sample is placed (e.g., mounted or otherwise immobilized) on a first substrate.
  • the first substrate can be any solid or semi-solid support upon which a biological sample can be mounted.
  • the first substrate is a slide.
  • the slide is a glass slide.
  • the substrate is made of glass, silicon, paper, hydrogel, polymer monoliths, or other material known in the art.
  • the first substrate is comprised of an inert material or matrix (e.g., glass slides) that has been functionalized by, for example, treating the substrate with a material comprising reactive groups which facilitate mounting of the biological sample.
  • the first substrate does not comprise a plurality (e.g., array) of capture probes, each comprising a spatial barcode.
  • a substrate e.g., a first substrate and/or a second substrate
  • a substrate can generally have any suitable form or format.
  • a substrate can be flat, curved, e.g., convexly or concavely curved.
  • a first substrate can be curved towards the area where the interaction between a biological sample, e.g., tissue sample, and a first substrate takes place.
  • a substrate is flat, e.g., planar, chip, or slide.
  • a substrate can contain one or more patterned surfaces within the first substrate (e.g., channels, wells, projections, ridges, divots, etc.).
  • a substrate e.g., a first substrate and/or second substrate
  • a substrate can be of any desired shape.
  • a substrate can be typically a thin, flat shape (e.g., a square or a rectangle).
  • a substrate structure has rounded comers (e.g., for increased safety or robustness).
  • a substrate structure has one or more cut-off corners (e.g., for use with a slide clamp or cross-table).
  • the substrate structure can be any appropriate type of support having a flat surface (e.g., a chip or a slide such as a microscope slide).
  • First and/or second substrates can optionally include various structures such as, but not limited to, projections, ridges, and channels.
  • a substrate can be micropattemed to limit lateral diffusion of analytes (e.g., to improve resolution of the spatial analysis).
  • a substrate modified with such structures can be modified to allow association of analytes, features (e.g., beads), or probes at individual sites.
  • the sites where a substrate is modified with various structures can be contiguous or non-contiguous with other sites.
  • the surface of a first and/or second substrate is modified to contain one or more wells, using techniques such as (but not limited to) stamping, microetching, or molding techniques.
  • the first substrate can be a concavity slide or cavity slide.
  • wells can be formed by one or more shallow depressions on the surface of the first and/or second substrate.
  • the wells can be formed by attaching a cassette (e.g., a cassette containing one or more chambers) to a surface of the first substrate structure.
  • first and/or second substrate is modified to contain one or more structures, including but not limited to, wells, projections, ridges, features, or markings
  • the structures can include physically altered sites.
  • a first and/or second substrate modified with various structures can include physical properties, including, but not limited to, physical configurations, magnetic or compressive forces, chemically functionalized sites, chemically altered sites, and/or electrostatically altered sites.
  • the structures are applied in a pattern. Alternatively, the structures can be randomly distributed.
  • a first substrate includes one or more markings on its surface, e.g., to provide guidance for aligning at least a portion of the biological sample with a plurality of capture probes on the second substrate during a sandwich process disclosed herein.
  • the first substrate can include a sample area indicator identifying the sample area.
  • the sample area indicator on the first substrate is aligned with an area of the second substrate comprising a plurality of capture probes.
  • the first and/or second substrate can include a fiducial mark.
  • the first and/or second substrate does not comprise a fiducial mark.
  • the first substrate does not comprise a fiducial mark and the second substrate comprises a fiducial mark.
  • markings can be made using techniques including, but not limited to, printing, sand-blasting, and depositing on the surface.
  • imaging can be performed using one or more fiducial markers, i.e., objects placed in the field of view of an imaging system which appear in the image produced.
  • Fiducial markers are typically used as a point of reference or measurement scale.
  • Fiducial markers can include, but are not limited to, detectable labels such as fluorescent, radioactive, chemiluminescent, and colorimetric labels. The use of fiducial markers to stabilize and orient biological samples is described, for example, in Carter etal., Applied Optics 46:421- 427, 2007), the entire contents of which are incorporated herein by reference.
  • a fiducial marker can be a physical particle (e.g., a nanoparticle, a microsphere, a nanosphere, a bead, a post, or any of the other exemplary physical particles described herein or known in the art).
  • a fiducial marker can be present on a first substrate to provide orientation of the biological sample.
  • a microsphere can be coupled to a first substrate to aid in orientation of the biological sample.
  • a microsphere coupled to a first substrate can produce an optical signal (e.g., fluorescence).
  • a quantum dot can be coupled to the first substrate to aid in the orientation of the biological sample.
  • a quantum dot coupled to a first substrate can produce an optical signal.
  • a fiducial marker can be an immobilized molecule with which a detectable signal molecule can interact to generate a signal.
  • a marker nucleic acid can be linked or coupled to a chemical moiety capable of fluorescing when subjected to light of a specific wavelength (or range of wavelengths).
  • a fiducial marker can be randomly placed in the field of view.
  • an oligonucleotide containing a fluorophore can be randomly printed, stamped, synthesized, or attached to a first substrate (e.g., a glass slide) at a random position on the first substrate.
  • a tissue section can be contacted with the first substrate such that the oligonucleotide containing the fluorophore contacts, or is in proximity to, a cell from the tissue section or a component of the cell (e.g., an mRNA or DNA molecule).
  • fiducial markers can be precisely placed in the field of view (e.g., at known locations on a first substrate).
  • a fiducial marker can be stamped, attached, or synthesized on the first substrate and contacted with a biological sample.
  • an image of the sample and the fiducial marker is taken, and the position of the fiducial marker on the first substrate can be confirmed by viewing the image.
  • a fiducial marker can be an immobilized molecule (e.g., a physical particle) attached to the first substrate.
  • a fiducial marker can be a nanoparticle, e.g., a nanorod, a nanowire, a nanocube, a nanopyramid, or a spherical nanoparticle.
  • the nanoparticle can be made of a heavy metal (e.g., gold).
  • the nanoparticle can be made from diamond.
  • the fiducial marker can be visible by eye.
  • first substrates can be any suitable support material.
  • exemplary first substrates include, but are not limited to, glass, modified and/or functionalized glass, hydrogels, films, membranes, plastics (including e.g., acrylics, polystyrene, copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonTM, cyclic olefins, polyimides etc.), nylon, ceramics, resins, Zeonor, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, optical fiber bundles, and polymers, such as polystyrene, cyclic olefin copolymers (COCs), cyclic olefin polymers (COPs), polypropylene, polyethylene polycarbonate, or combinations thereof.
  • plastics including e.g., acrylics, polystyrene, copolymers of styrene
  • polystyrene is a hydrophobic material suitable for binding negatively charged macromolecules because it normally contains few hydrophilic groups.
  • nucleic acids immobilized on glass slides by increasing the hydrophobicity of the glass surface the nucleic acid immobilization can be increased.
  • Such an enhancement can permit a relatively more densely packed formation (e.g., provide improved specificity and resolution).
  • a first substrate can be a flow cell.
  • Flow cells can be formed of any of the foregoing materials, and can include channels that permit reagents, solvents, features, and analytes to pass through the flow cell.
  • a hydrogel embedded biological sample is assembled in a flow cell (e.g., the flow cell is utilized to introduce the hydrogel to the biological sample).
  • a hydrogel embedded biological sample is not assembled in a flow cell.
  • the hydrogel embedded biological sample can then be prepared and/or isometrically expanded as described herein.
  • Exemplary substrates similar to the first substrate (e.g., a substrate having no capture probes) and/or the second substrate are described in Section (I) above and in WO 2020/123320, which is hereby incorporated by reference in its entirety.
  • RNA-templated ligation to detect the analyte.
  • spatial “RNA- templated ligation,” or “RTL” or simply “templated ligation” is a process where individual probe oligonucleotides (e.g., a first probe oligonucleotide, a second probe oligonucleotide) in a probe pair hybridize to adjacent sequences of an analyte (e.g., an RNA molecule) in a biological sample (e.g., a tissue sample).
  • RNA-templated ligation is disclosed in PCT Publ. No. WO 2021/133849 Al and US Publ. No. US 2021/0285046 Al, each of which is incorporated by reference in its entirety.
  • an advantage to using RTL is that it allows for enhanced detection of analytes (e.g., low expressing analytes) because both probe oligonucleotides must hybridize to the analyte in order for the coupling (e.g., ligating) reaction to occur.
  • “coupling” refers to an interaction between two probe oligonucleotides that results in a single connected probe that comprises the two probe oligonucleotides. In some instances, coupling is achieved through ligation. In some instances, coupling is achieved through extension of one probe oligonucleotide to the second probe oligonucleotide followed by ligation.
  • coupling is achieved through hybridization (e.g., using a third probe oligonucleotide that hybridized to each of the two probe oligonucleotides) followed by extension of one probe oligonucleotide or gap filling of the sequence between the two probe oligonucleotides using the third probe oligonucleotide as a template.
  • the connected probe (e.g., ligation product) that results from the coupling (e.g., ligation) of the two probe oligonucleotides can serve as a proxy for the target analyte, as such an analyte derived molecule.
  • probe oligonucleotide pairs can be designed to cover any gene of interest.
  • a pair of probe oligonucleotides can be designed so that each analyte, e.g., a whole exome, a transcriptome, a genome, can conceivably be detected using a probe oligonucleotide pair.
  • Also provided herein are methods for analyzing an analyte in a biological sample mounted on a first substrate including (a) hybridizing a first probe oligonucleotide and a second probe oligonucleotide to the analyte, where the first probe oligonucleotide and the second probe oligonucleotide each include a sequence that is substantially complementary to adjacent sequences of the analyte, and where the second probe oligonucleotide includes a capture probe binding domain; (b) coupling (e.g., ligating) the first probe oligonucleotide and the second probe oligonucleotide, thereby generating a connected probe (e.g., a ligation product) including the capture probe binding domain; (c) aligning the first substrate with a second substrate including an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, where the array includes a plurality of capture probe
  • the process of transferring the connected probe (e.g., a ligation product) from the first substrate to the second substrate is referred to as a “sandwich” process.
  • the sandwich process is described in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety. Described herein are methods in which an array with capture probes located on a substrate and a biological sample located on a different substrate, are contacted such that the array is in contact with the biological sample (e.g., the substrates are sandwiched together). In some embodiments, the array and the biological sample can be contacted (e.g., sandwiched), without the aid of a substrate holder.
  • the array and biological sample substrates can be placed in a substrate holder (e.g., an array alignment device) designed to align the biological sample and the array.
  • the substrate holder can have placeholders for two substrates.
  • an array including capture probes can be positioned on one side of the substrate holder (e.g., in a first substrate placeholder).
  • a biological sample can be placed on the adjacent side of the substrate holder in a second placeholder.
  • a hinge can be located between the two substrate placeholders that allows the substrate holder to close, e.g., make a sandwich between the two substrate placeholders.
  • the biological sample and the array with capture probes are contacted with one another under conditions sufficient to allow analytes present in the biological sample to interact with the capture probes of the array.
  • dried permeabilization reagents can be placed on the biological sample and rehydrated.
  • a permeabilization solution can be flowed through the substrate holder to permeabilize the biological sample and allow analytes in the biological sample to interact with the capture probes.
  • the temperature of the substrates or permeabilization solution can be used to initiate or control the rate of permeabilization.
  • the substrate including the array, the substrate including the biological sample, or both substrates can be held at a low temperature to slow diffusion and permeabilization efficiency.
  • the substrates can be heated to initiate permeabilization and/or increase diffusion efficiency. Transcripts that are released from the permeabilized tissue can diffuse to the array and be captured by the capture probes. The sandwich can be opened, and cDNA synthesis can be performed on the array.
  • the methods as disclosed herein include hybridizing of one or more probe oligonucleotide probe pairs (e.g., RTL probes) to adjacent or nearby sequences of a target analyte (e.g., RNA; e.g., mRNA) of interest.
  • a target analyte e.g., RNA; e.g., mRNA
  • the probe oligonucleotide pairs include sequences that are complementary or substantially complementary to an analyte.
  • each probe oligonucleotide includes a sequence that is complementary or substantially complementary to an mRNA of interest (e.g., to a portion of the sequence of an mRNA of interest).
  • each target analyte includes a first target region and a second target region.
  • the methods include providing a plurality of first probe oligonucleotides and a plurality of second probe oligonucleotides, where a pair of probe oligonucleotides for a target analyte comprises both a first and second probe oligonucleotide.
  • a first probe oligonucleotide hybridizes to a first target region of the analyte
  • the second probe oligonucleotide hybridizes to a second, adjacent or nearly adjacent target region of the analyte.
  • the probe oligonucleotides are DNA molecules.
  • the first probe oligonucleotide is a DNA molecule.
  • the second probe oligonucleotide is a DNA molecule.
  • the first probe oligonucleotide comprises at least two ribonucleic acid bases at the 3’ end.
  • the second probe oligonucleotide comprises a phosphorylated nucleotide at the 5’ end.
  • RTL probes can be designed using methods known in the art.
  • probe pairs are designed to cover an entire transcriptome of a species (e.g., a mouse or a human).
  • RTL probes are designed to cover a subset of a transcriptome e.g., a mouse or a human).
  • the methods disclosed herein utilize about 500, about 1000, about 2000, about 3000, about 4000, about 5000, about 6000, about 7000, about 8000, about 9000, about 10,000, about 15,000, about 20,000, or more probe pairs.
  • one of the probe oligonucleotides of the pair of probe oligonucleotides for RTL includes a poly(A) sequence or a complement thereof. In some instances, the poly(A) sequence or a complement thereof is on the 5’ end of one of the probe oligonucleotides. In some instances, the poly(A) sequence or a complement thereof is on the 3’ end of one of the probe oligonucleotides. In some embodiments, one probe oligonucleotide of the pair of probe oligonucleotides for RTL includes a degenerate or UMI sequence. In some embodiments, the UMI sequence is specific to a particular target or set of targets.
  • the UMI sequence or a complement thereof is on the 5’ end of one of the probe oligonucleotides. In some instances, the UMI sequence or a complement thereof is on the 3’ end of one of the probe oligonucleotides.
  • the first and second target regions of an analyte are directly adjacent to one another.
  • the complementary sequences to which the first probe oligonucleotide and the second probe oligonucleotide hybridize are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 125, or about 150 nucleotides away from each other.
  • Gaps between the probe oligonucleotides may first be filled prior to coupling (e.g., ligation), using, for example, dNTPs in combination with a polymerase such as polymerase mu, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase, and/or any combinations, derivatives, and variants (e.g., engineered mutants) thereof.
  • a polymerase such as polymerase mu, DNA polymerase, RNA polymerase, reverse transcriptase, VENT polymerase, Taq polymerase, and/or any combinations, derivatives, and variants (e.g., engineered mutants) thereof.
  • deoxyribonucleotides are used to extend and couple (e.g., ligate) the first and second probe oligonucleotides.
  • the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on the same transcript. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on the same exon. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte on different exons. In some instances, the first probe oligonucleotide and the second probe oligonucleotide hybridize to an analyte that is the result of a translocation event (e.g., in the setting of cancer).
  • a translocation event e.g., in the setting of cancer
  • the methods provided herein make it possible to identify alternative splicing events, translocation events, and mutations that change the hybridization rate of one or both probe oligonucleotides (e.g., single nucleotide polymorphisms (SNPs), insertions, deletions, point mutations).
  • probe oligonucleotides e.g., single nucleotide polymorphisms (SNPs), insertions, deletions, point mutations.
  • the first and/or second probe as disclosed herein includes at least two ribonucleic acid bases at the 3’ end; a functional sequence; a phosphorylated nucleotide at the 5’ end; and/or a capture probe binding domain.
  • the functional sequence is a primer sequence.
  • the “capture probe binding domain” is a sequence that is complementary to a particular capture domain present in a capture probe.
  • the capture probe binding domain includes a poly(A) sequence.
  • the capture probe binding domain includes a poly-uridine sequence, a poly-thymidine sequence, or a combination thereof.
  • the capture probe binding domain includes a random sequence (e.g., a random hexamer or octamer).
  • the capture probe binding domain is complementary to a capture domain in a capture probe that detects a particular target(s) of interest.
  • a capture probe binding domain blocking moiety that interacts with the capture probe binding domain is provided.
  • a capture probe binding domain blocking moiety includes a sequence that is complementary or substantially complementary to a capture probe binding domain. In some embodiments, a capture probe binding domain blocking moiety prevents the capture probe binding domain from binding the capture probe when present. In some embodiments, a capture probe binding domain blocking moiety is removed prior to binding the capture probe binding domain (e.g., present in a connected probe (e.g., a ligation product)) to a capture probe. In some embodiments, a capture probe binding domain blocking moiety comprises a poly-uridine sequence, a poly-thymidine sequence, or a combination thereof.
  • Hybridization of the probe oligonucleotides to the target analyte can occur at a target having a sequence that is 100% complementary to the probe oligonucleotide(s).
  • hybridization can occur at a target having a sequence that is at least (e.g., at least about) 80%, at least (e.g., at least about) 85%, at least (e.g., at least about) 90%, at least (e.g., at least about) 95%, at least (e.g., at least about) 96%, at least (e.g., at least about) 97%, at least (e.g., at least about) 98%, or at least (e.g., at least about) 99% complementary to the probe oligonucleotide(s).
  • the first probe oligonucleotide is extended.
  • the second probe oligonucleotide is extended. For example, in some instances a first probe oligonucleotide hybridizes to a target sequence upstream for a second oligonucleotide probe, whereas in other instances a first probe oligonucleotide hybridizes to a target sequence downstream of a second probe oligonucleotide.
  • methods disclosed herein include a wash step after hybridizing the first and the second probe oligonucleotides.
  • the wash step removes any unbound oligonucleotides and can be performed using any technique known in the art.
  • a pre-hybridization buffer is used to wash the sample.
  • a phosphate buffer is used.
  • multiple wash steps are performed to remove unbound oligonucleotides. For example, it is advantageous to decrease the amount of unhybridized probes present in a biological sample as they may interfere with downstream applications and methods.
  • probe oligonucleotides e.g., first and the second probe oligonucleotides
  • the probe oligonucleotides are coupled (e.g., ligated) together, creating a single connected probe (e.g., a ligation product) that is complementary to the target analyte.
  • Ligation can be performed enzymatically or chemically, as described herein.
  • the first and second probe oligonucleotides are hybridized to the first and second target regions of the analyte, and the probe oligonucleotides are subjected to a nucleic acid reaction to ligate them together.
  • the probes may be subjected to an enzymatic ligation reaction using a ligase (e.g., T4 RNA ligase (Rnl2), a SplintR ligase, or a T4 DNA ligase).
  • a ligase e.g., T4 RNA ligase (Rnl2), a SplintR ligase, or a T4 DNA ligase.
  • the first probe oligonucleotide and the second probe oligonucleotides are on a contiguous nucleic acid sequence. In some embodiments, the first probe oligonucleotide is on the 3’ end of the contiguous nucleic acid sequence. In some embodiments, the first probe oligonucleotide is on the 5’ end of the contiguous nucleic acid sequence. In some embodiments, the second probe oligonucleotide is on the 3’ end of the contiguous nucleic acid sequence. In some embodiments, the second probe oligonucleotide is on the 5’ end of the contiguous nucleic acid sequence.
  • the method further includes hybridizing a third probe oligonucleotide to the first probe oligonucleotide and the second probe oligonucleotide such that the first probe oligonucleotide and the second probe oligonucleotide abut each other.
  • the third probe oligonucleotide comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to a portion of the first probe oligonucleotide that hybridizes to the third probe oligonucleotide.
  • the third probe oligonucleotide comprises a sequence that is 100% complementary to a portion of the first probe oligonucleotide that hybridizes to the third probe oligonucleotide. In some embodiments, the third probe oligonucleotide comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to a portion of the second probe oligonucleotide that hybridizes to the third probe oligonucleotide. In some embodiments, the third probe oligonucleotide comprises a sequence that is 100% complementary to a portion of the second probe oligonucleotide that hybridizes to the third probe oligonucleotide.
  • a method for identifying a location of an analyte in a biological sample exposed to different permeabilization conditions includes (a) contacting the biological sample with a substrate, where the substrate comprises a plurality of capture probes, where a capture probe of the plurality of capture probes comprises a capture domain; (b) contacting the biological sample with a first probe oligonucleotide and a second probe oligonucleotide, where the first probe oligonucleotide and the second probe oligonucleotide are substantially complementary to adjacent sequences of the analyte, and where the second probe oligonucleotide comprises a capture probe-binding domain that is capable of binding to a capture domain of the capture probe; (c) hybridizing the first probe oligonucleotide and the second probe oligonucleotide to adjacent sequences of the analyte; (d) coupling (e.g., ligating) the first probe oligon
  • the method further includes amplifying the connected probe (e.g., a ligation product) prior to the releasing step.
  • the entire connected probe e.g., a ligation product
  • only part of the connected probe e.g., a ligation product
  • amplification is isothermal. In some embodiments, amplification is not isothermal.
  • Amplification can be performed using any of the methods described herein such as, but not limited to, a strand-displacement amplification reaction, a rolling circle amplification reaction, a ligase chain reaction, a transcription-mediated amplification reaction, an isothermal amplification reaction, and/or a 10 loop-mediated amplification reaction.
  • amplifying the connected probe e.g., a ligation product
  • amplifying the connected probe creates an amplified connected probe (e.g., a ligation product) that includes (i) all or part of sequence of the connected probe (e.g., a ligation product) specifically bound to the capture domain, or a complement thereof, and (ii) the sequence of the spatial barcode, or a complement thereof.
  • the method further includes determining (i) all or a part of the sequence of the connected probe (e.g., a ligation product), or a complement thereof, and (ii) the sequence of the spatial barcode, or a complement thereof. In some embodiments, the method further includes using the determined sequence of (i) and (ii) to determine the location and abundance of the analyte in the biological sample. [00169] In some embodiments, after coupling (e.g., ligation) of the first and second probe oligonucleotides to create a ligation product, the connected probe (e.g., a ligation product) is released from the analyte.
  • the connected probe e.g., a ligation product
  • an endoribonuclease e.g., RNase A, RNase C, RNase H, or RNase I
  • An endoribonuclease such as RNase H specifically cleaves RNA in RNA:DNA hybrids.
  • the connected probe e.g., a ligation product
  • the connected probe e.g., a ligation product
  • an endoribonuclease is used to release the probe from the analyte.
  • the endoribonuclease is one or more of RNase H.
  • the RNase H is RNase Hl or RNase H2.
  • the releasing of the connected probe includes contacting the biological sample with a reagent medium comprising a permeabilization agent and an agent for releasing the connected probe (e.g., a ligation product), thereby permeabilizing the biological sample and releasing the connected probe (e.g., a ligation product) from the analyte.
  • the agent for releasing the connected probe comprises a nuclease.
  • the nuclease is an endonuclease.
  • the nuclease is an exonuclease.
  • the nuclease includes an RNase.
  • the RNase is selected from RNase A, RNase C, RNase H, or RNase I.
  • the reagent medium comprises polyethylene glycol (PEG).
  • the PEG is from about PEG 2K to about PEG 16K.
  • the PEG is PEG 2K, 3K, 4K, 5K, 6K, 7K, 8K, 9K, 10K, 1 IK, 12K, 13K, 14K, 15K, or 16K.
  • the PEG is present at a concentration from about 2% to 25%, from about 4% to about 23%, from about 6% to about 21%, or from about 8% to about 20% (v/v).
  • the reagent medium includes a wetting agent.
  • the methods disclosed herein include simultaneous treatment of the biological sample with a permeabilization agent such as proteinase K (to permeabilize the biological sample) and a releasing agent such as an endonuclease such as RNase H (to release the connected probe (e.g., a ligation product) from the analyte).
  • a permeabilization agent such as proteinase K (to permeabilize the biological sample)
  • a releasing agent such as an endonuclease such as RNase H
  • the permeabilization step and releasing step occur at the same time.
  • the permeabilization step occurs before the releasing step.
  • the permeabilization agent comprises a protease.
  • the protease is selected from trypsin, pepsin, elastase, or Proteinase K.
  • the protease is an endopeptidase.
  • Endopeptidases that can be used include but are not limited to trypsin, chymotrypsin, elastase, thermolysin, pepsin, clostripan, glutamyl endopeptidase (GluC), ArgC, peptidyl-asp endopeptidase (ApsN), endopeptidase LysC and endopeptidase LysN.
  • the endopeptidase is pepsin.
  • the reagent medium further includes a detergent.
  • the detergent is selected from sodium dodecyl sulfate (SDS), sarkosyl, saponin, Triton X-100TM, or Tween-20TM
  • the reagent medium includes less than 5 w/v% of a detergent selected from sodium dodecyl sulfate (SDS) and sarkosyl.
  • the reagent medium includes as least 5% w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium does not include SDS or sarkosyl.
  • the biological sample and the array are contacted with the reagent medium for about 1 to about 60 minutes (e.g., about 1 to about 55 minutes, about 1 to about 50 minutes, about 1 to about 45 minutes, about 1 to about 40 minutes, about 1 to about 35 minutes, about 1 to about 30 minutes, about 1 to about 25 minutes, about 1 to about 20 minutes, about 1 to about 15 minutes, about 1 to about 10 minutes, about 1 to about 5 minutes, about 5 to about 60 minutes, about 5 to about 55 minutes, about 5 to about 50 minutes, about 5 to about 45 minutes, about 5 to about 40 minutes, about 5 to about 35 minutes, about 5 to about 30 minutes, about 5 to about 25 minutes, about 5 to about 20 minutes, about 5 to about 15 minutes, about 5 to about 10 minutes, about 10 to about 60 minutes, about 10 to about 55 minutes, about 10 to about 50 minutes, about 10 to about 45 minutes, about 10 to about 40 minutes, about 10 to about 35 minutes, about 10 to about 30 minutes, about 10 to about 25 minutes, about 10 to about 20 minutes, about 5 to about 15 minutes, about 5
  • the connected probe (e.g., a ligation product) includes a capture probe binding domain, which can hybridize to a capture probe (e.g., a capture probe immobilized, directly or indirectly, on a substrate).
  • the capture probe includes a spatial barcode and the capture domain.
  • the capture probe binding domain of the connected probe (e.g., a ligation product) specifically binds to the capture domain of the capture probe.
  • methods provided herein include mounting a biological sample on a first substrate, then aligning the first substrate with a second substrate including an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, where the array includes a plurality of capture probes. After hybridization of the connected probe (e.g., a ligation product) to the capture probe, downstream methods as disclosed herein can be performed.
  • a biological sample e.g., a ligation product
  • At least 50% of connected probes (e.g., a ligation products) released from the portion of the biological sample aligned with the portion of the array are captured by capture probes of the portion of the array.
  • at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of connected probe (e.g., a ligation products) are detected in spots directly under the biological sample.
  • the capture probe includes a poly(T) sequence. In some embodiments, capture probe includes a sequence specific to the analyte. In some embodiments, the capture probe includes a functional domain. In some embodiments, the capture probe further includes one or more functional domains, a unique molecular identifier (UMI), a cleavage domain, and combinations thereof. In some embodiments, the capture probe binding domain includes a poly(A) sequence. In some embodiments, the capture probe binding domain includes a sequence complementary to a capture domain of a capture probe that detects a target analyte of interest. In some embodiments, the analyte is RNA. In some embodiments, the analyte is mRNA.
  • the connected probe e.g, a ligation product
  • the analyte derived molecule includes a capture probe binding domain, which can hybridize to a capture probe (e.g., a capture probe immobilized, directly or indirectly, on a substrate).
  • Methods provided herein include contacting a biological sample with a substrate, where the capture probe is affixed to the substrate (e.g., immobilized to the substrate, directly or indirectly).
  • downstream methods as disclosed herein e.g., sequencing, in situ analysis such as RCA
  • the method further includes analyzing a different analyte in the biological sample.
  • the analysis of the different analyte includes (a) further contacting the biological sample with a plurality of analyte capture agents, where an analyte capture agent of the plurality of analyte capture agents includes an analyte binding moiety and a capture agent barcode domain, where the analyte binding moiety specifically binds to the different analyte, and where the capture agent barcode domain includes an analyte binding moiety barcode and an capture handle sequence that is complementary to a capture domain of a capture probe; and (b) hybridizing the analyte capture sequence to the capture domain.
  • FIG. 7A An exemplary embodiment of a workflow for analysis of protein and RNA analytes is shown in FIG. 7A.
  • a fixed tissue sample mounted on a first substrate e.g., a slide-mounted tissue sample
  • a first and second probe of a probe pair is connected, e.g., ligated.
  • the sample is optionally washed (e.g., with a buffer), prior to incubation with an analyte capture agent (e.g., an antibody) that specifically binds a different analyte, e.g., a protein analyte.
  • analyte capture agent e.g., an antibody
  • the analyte capture agent comprises a capture agent barcode domain.
  • the analyte capture agent is an antibody with an oligonucleotide tag, the oligonucleotide tag comprising a capture agent barcode domain.
  • the connected probes (e.g., the ligation products) and antibody oligonucleotide tags are released from the tissue under sandwich conditions as described herein.
  • the tissue-mounted slide can be aligned with an array and permeabilized with a reagent medium in the sandwich configuration as described herein (see, e.g., FIG. 7B).
  • the reagent medium comprises RNase and a permeabilization agent (e.g., Proteinase K).
  • Permeabilization releases the connected probe (e.g., a ligation product) and capture agent barcode domain, for capture onto a second substrate comprising an array with a plurality of capture probes (see, e.g., FIG. 7B).
  • the tissue slide can be removed (e.g., the sandwich can be “opened” or “broken”).
  • the capture probes can be extended, sequencing libraries can be prepared and sequenced, and the results can be analyzed computationally.
  • the method further includes determining (i) all or part of the sequence of the capture agent barcode domain; and (ii) the sequence of the spatial barcode, or a complement thereof. In some embodiments, the method further includes using the determined sequence of (i), and (ii) to analyze the different analyte in the biological sample. In some embodiments, the releasing step further releases the capture agent barcode domain from the different analyte.
  • the different analyte is a protein analyte. In some embodiments, the protein analyte is an extracellular protein. In some embodiments, the protein analyte is an intracellular protein.
  • analyte capture agent refers to a molecule that interacts with a target analyte (e.g., a protein) and with a capture probe. Such analyte capture agents can be used to identify the analyte.
  • the analyte capture agent can include an analyte binding moiety and a capture agent barcode domain.
  • the analyte capture agent includes a linker. In some embodiments, the linker is a cleavable linker.
  • the cleavable linker is a photo-cleavable linker, a UV-cleavable linker, or an enzyme cleavable linker.
  • the cleavable linker is a disulfide linker.
  • a disulfide linker can be cleaved by use of a reducing agent, such as dithiothreitol (DTT), Beta-mercaptoethanol (BME), or Tris (2-carboxyethyl) phosphine (TCEP).
  • An analyte binding moiety is a molecule capable of binding to a specific analyte.
  • the analyte binding moiety comprises an antibody or antibody fragment.
  • the analyte binding moiety comprises a polypeptide and/or an aptamer.
  • the analyte is a protein (e.g., a protein on a surface of a cell or an intracellular protein).
  • a capture agent barcode domain can include a capture handle sequence which can hybridize to at least a portion or an entirety of a capture domain of a capture probe.
  • the capture handle sequence is complementary to a portion or entirety of a capture domain of a capture probe.
  • the capture handle sequence includes a poly (A) tail.
  • the capture handle sequence includes a sequence capable of binding a poly (T) domain.
  • the capture agent barcode domain comprises an analyte binding moiety barcode and a capture handle sequence.
  • the analyte binding moiety barcode refers to a barcode that is associated with or otherwise identifies the analyte binding moiety, and the capture handle sequence can hybridize to a capture probe.
  • the capture handle sequence specifically binds to the capture domain of the capture probe.
  • Other embodiments of an analyte capture agent useful in spatial analyte detection are described herein.
  • analyte capture agent of the plurality of analyte capture agents includes an analyte binding moiety and a capture agent barcode domain, where the analyte binding moiety specifically binds to the analyte, and where the capture agent barcode domain includes an analyte binding moiety barcode and an capture handle sequence;
  • a reagent medium including an agent for releasing the capture agent barcode domain from the analyte binding moiety, thereby releasing the capture agent barcode domain from the analyte binding moiety; and (c) hybridizing the capture handle sequence to a capture domain of a capture probe, where the capture probe includes (i) a spatial barcode and (ii) a capture domain.
  • Also provided herein are methods for analyzing an analyte in a biological sample mounted on a first substrate including (a) contacting the biological sample with a plurality of analyte capture agents, where an analyte capture agent of the plurality of analyte capture agents includes an analyte binding moiety and a capture agent barcode domain, where the analyte binding moiety specifically binds to the analyte, and where the capture agent barcode domain includes an analyte binding moiety barcode and an capture handle sequence; (b) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, where the array includes a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain; (c) when the biological sample is aligned with at least a portion of the array, (i) releasing
  • Also provided herein are methods for analyzing an analyte in a biological sample mounted on a first substrate including (a) contacting the biological sample with a plurality of analyte capture agents, where an analyte capture agent of the plurality of analyte capture agents includes an analyte binding moiety and a capture agent barcode domain, where the analyte binding moiety specifically binds to the analyte, and where the capture agent barcode domain includes an analyte binding moiety barcode and an capture handle sequence; (b) aligning the first substrate with a second substrate comprising an array, such that at least a portion of the biological sample is aligned with at least a portion of the array, where the array includes a plurality of capture probes, where a capture probe of the plurality of capture probes includes (i) a spatial barcode and (ii) a capture domain; (c) when the biological sample is aligned with at least a portion of the array, (i) releasing
  • the process of transferring the connected probe (e.g., a ligation product) from the first substrate to the second substrate is referred to as a “sandwich process”.
  • the sandwich process is described above and in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the method further includes determining (i) all or a part of the capture agent barcode domain, or a complement thereof; and (ii) the sequence of the spatial barcode, or a complement thereof. In some embodiments, the method further includes using the determined sequence of (i) and (ii) to determine the location and abundance of the analyte in the biological sample.
  • an analyte capture agent is introduced to a biological sample, where the analyte binding moiety specifically binds to a target analyte, and then the biological sample can be treated to release the capture agent barcode domain from the biological sample.
  • the capture agent barcode domain can then migrate and bind to a capture domain of a capture probe, and the capture agent barcode domain can be extended to generate a spatial barcode complement at the end of the capture agent barcode domain.
  • the spatially-tagged capture agent barcode domain can be denatured from the capture probe, and analyzed using methods described herein.
  • the releasing includes contacting the biological sample and the array with a reagent medium including a nuclease.
  • the nuclease includes an RNase.
  • the RNase is selected from RNase A, RNase C, RNase H, and RNase I.
  • the reagent medium further includes a permeabilization agent.
  • the releasing further includes simultaneously permeabilizing the biological sample and releasing the capture agent barcode domain from the analyte.
  • the permeabilization agent further includes a protease.
  • the protease is selected from trypsin, pepsin, elastase, or Proteinase K.
  • the capture agent barcode domain is released from the analyte binding moiety by using a different stimulus that can include, but is not limited to, a proteinase (e.g., Proteinase K), an RNase, and UV light.
  • a proteinase e.g., Proteinase K
  • RNase RNase
  • UV light UV light
  • the reagent medium further includes a detergent.
  • the detergent is selected from sodium dodecyl sulfate (SDS), sarkosyl, saponin, Triton X-100TM, or Tween-20TM
  • the reagent medium includes less than 5 w/v% of a detergent selected from sodium dodecyl sulfate (SDS) and sarkosyl.
  • the reagent medium includes as least 5% w/v% of a detergent selected from SDS and sarkosyl.
  • the reagent medium does not include SDS or sarkosyl.
  • the biological sample and the array are contacted with the reagent medium for about 1 to about 60 minutes (e.g., about 1 to about 55 minutes, about 1 to about 50 minutes, about 1 to about 45 minutes, about 1 to about 40 minutes, about 1 to about 35 minutes, about 1 to about 30 minutes, about 1 to about 25 minutes, about 1 to about 20 minutes, about 1 to about 15 minutes, about 1 to about 10 minutes, about 1 to about 5 minutes, about 5 to about 60 minutes, about 5 to about 55 minutes, about 5 to about 50 minutes, about 5 to about 45 minutes, about 5 to about 40 minutes, about 5 to about 35 minutes, about 5 to about 30 minutes, about 5 to about 25 minutes, about 5 to about 20 minutes, about 5 to about 15 minutes, about 5 to about 10 minutes, about 10 to about 60 minutes, about 10 to about 55 minutes, about 10 to about 50 minutes, about 10 to about 45 minutes, about 10 to about 40 minutes, about 10 to about 35 minutes, about 10 to about 30 minutes, about 10 to about 25 minutes, about 10 to about 20 minutes, about 5 to about 15 minutes, about 5
  • the analysis of the different analyte includes (a) hybridizing a first probe oligonucleotide and a second probe oligonucleotide to the different analyte, where the first probe oligonucleotide and the second probe oligonucleotide each comprise a sequence that is substantially complementary to adjacent sequences of the different analyte, and where the second probe oligonucleotide comprises a capture probe binding domain; (b) ligating the first probe oligonucleotide and the second probe oligonucleotide, thereby generating a connected probe (e.g., a ligation product) comprising the capture probe binding domain; and (c) hybridizing the capture probe binding domain of the connected probe (e.g., a ligation product) to the capture domain.
  • a connected probe e.g., a ligation product
  • the method further includes determining (i) all or part of the sequence of the connected probe (e.g., a ligation product), or a complement thereof, and (ii) the sequence of the spatial barcode, or a complement thereof. In some embodiments, the method further includes using the determined sequence of (i), and (ii) to analyze the different analyte in the biological sample. In some embodiments, the releasing step further releases the connected probe (e.g., a ligation product) from the different analyte. In some embodiments, the different analyte is RNA. In some embodiments, the different analyte is mRNA.
  • the capture probe comprises a poly(T) sequence. In some embodiments, the capture probe comprises a sequence complementary to the capture handle sequence. In some embodiments, the capture probe comprises a functional domain. In some embodiments, the capture probe further comprises one or more functional domains, a unique molecular identifier (UMI), a cleavage domain, and combinations thereof.
  • UMI unique molecular identifier
  • the biological sample is a tissue sample.
  • the tissue sample is a tissue section.
  • the tissue sample is a fixed tissue sample.
  • the fixed tissue sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
  • the FFPE tissue is deparaffinized and decrosslinked prior to step (a) of any one of the methods provided herein.
  • the fixed tissue sample is a formalin fixed paraffin embedded cell pellet.
  • the tissue sample is a fresh tissue sample or a frozen tissue sample.
  • the tissue sample is fixed and stained prior to step (a) of any one of the methods provided herein.
  • RTL is performed between two oligonucleotides that each are affixed to an analyte binding moiety (i.e., a protein-binding moiety).
  • analyte binding moiety i.e., a protein-binding moiety.
  • a method of determining a location of at least one analyte in a biological sample including: (a) hybridizing a first analyte-binding moiety to a first analyte in the biological sample, where the first analytebinding moiety is bound to a first oligonucleotide, where the first oligonucleotide comprises: (i) a functional sequence; (ii) a first barcode; and (iii) a first bridge sequence; (b) hybridizing a second analyte-binding moiety to a second analyte in the biological sample, where the second analytebinding moiety is bound to a second oligonucleotide; where the second oligonucleotide comprises: (i) capture probe binding domain sequence, (ii) a second barcode; and (ii) a second bridge sequence; (c) contacting the biological sample with a third oligonucle
  • two analytes e.g., two different proteins
  • a first analyte-binding moiety and/or the second analyte-binding moiety is an analyte capture agent (e.g., any of the exemplary analyte capture agents described herein).
  • the first analyte-binding moiety and/or the second analyte-binding moiety is a first protein.
  • the first analyte-binding moiety and/or the second analyte-binding moiety is an antibody.
  • the antibody can include, without limitation, a monoclonal antibody, recombinant antibody, synthetic antibody, a single domain antibody, a single-chain variable fragment (scFv), and or an antigen-binding fragment (Fab).
  • the first analyte-binding moiety binds to a cell surface analyte (e.g., any of the exemplary cell surface analytes described herein).
  • binding of the analyte is performed metabolically.
  • binding of the analyte is performed enzymatically.
  • the methods include a secondary antibody that binds to a primary antibody, enhancing its detection.
  • the first analyte-binding moiety and the second analytebinding moiety each bind to the same analyte. In some embodiments, the first analyte-binding moiety and/or second analyte-binding moiety each bind to a different analyte. For example, in some embodiments, the first analyte-binding moiety binds to a first polypeptide and the second analyte-binding moiety binds to a second polypeptide.
  • a first and/or a second oligonucleotide are bound (e.g., conjugated or otherwise attached using any of the methods described herein) to a first analyte-binding moiety and/or a second analyte-binding moiety, respectively.
  • a second oligonucleotide is bound (e.g., conjugated or otherwise attached using any of the methods described herein) to a second analytebinding moiety.
  • the second oligonucleotide can be covalently linked to the second analyte-binding moiety.
  • the second oligonucleotide is bound to the second analyte-binding moiety via its 5’ end.
  • the second oligonucleotide includes a free 3’ end.
  • the second oligonucleotide is bound to the second analytebinding moiety via its 3’ end.
  • the second oligonucleotide includes a free 5’ end.
  • the oligonucleotides are bound to the first and/or second analyte-binding moi eties via a linker (e.g., any of the exemplary linkers described herein).
  • the linker is a cleavable linker.
  • the linker is a linker with photo-sensitive chemical bonds (e.g., photo-cleavable linkers).
  • the linker is a cleavable linker that can undergo induced dissociation.
  • FIGs. 8A-8B show exemplary schematics illustrating methods to release the capture agent barcode domain from the analyte binding moiety.
  • FIG. 8A shows the use of an RNase cleavable linker to release a capture agent barcode domain from an analyte binding moiety of an analyte capture agent.
  • a target indicated by the circle in FIG. 8A interacts with an antibody.
  • an enzyme e.g., an RNAse
  • FIG. 8B shows the use of a UV cleavable linker to release a capture agent barcode domain from an analyte binding moiety of an analyte capture agent.
  • the oligonucleotides are bound (e.g., attached via any of the methods described herein) to an analyte-binding domain via a 5’ end.
  • a barcode is used to identify the analyte-binding moiety to which it is bound.
  • the barcode can be any of the exemplary barcodes described herein.
  • the first and/or second oligonucleotide include a capture probe binding domain sequence.
  • a capture probe binding domain sequence can be a poly(A) sequence when the capture domain sequence is a poly(T) sequence.
  • a third oligonucleotide hybridizes to both the first and second oligonucleotides and enables ligation of the first oligonucleotide and the second oligonucleotide.
  • a ligase is used.
  • the ligase includes a DNA ligase.
  • the ligase includes an RNA ligase.
  • the ligase includes T4 DNA ligase.
  • the ligase is a SplintR ligase.
  • one or more analytes from the biological sample are released from the biological sample and migrate to a substrate comprising an array of capture probes for attachment to the capture probes of the array.
  • the release and migration of the analytes to the substrate comprising the array of capture probes occurs in a manner that preserves the original spatial context of the analytes in the biological sample.
  • the biological sample is mounted on a first substrate and the substrate comprising the array of capture probes is a second substrate.
  • the alignment of the first substrate and the second substrate is facilitated by a sandwiching process. Accordingly, described herein are methods, compositions, devices, and systems for sandwiching together the first substrate as described herein with a second substrate having an array with capture probes.
  • FIG. 9 is a schematic diagram depicting an exemplary sandwiching process between a first substrate comprising a biological sample (e.g., a tissue section 902 on a slide 903) and a second substrate comprising a spatially barcoded array, e.g., a slide 904 that is populated with spatially-barcoded capture probes 906.
  • the first substrate is aligned with the second substrate, such that at least a portion of the biological sample is aligned with at least a portion of the array (e.g., aligned in a sandwich configuration).
  • the second substrate e.g., slide 904 is in a superior position to the first substrate (e.g., slide 903).
  • the first substrate e.g., slide 903
  • the second substrate e.g., slide 904
  • the first and second substrates are aligned to maintain a gap or separation distance 907 between the two substrates.
  • one or more analytes are released from the biological sample and actively or passively migrate to the array for capture.
  • the migration occurs while the aligned portions of the biological sample and the array are contacted with a reagent medium 905.
  • the released one or more analytes may actively or passively migrate across the gap 907 via the reagent medium 905 toward the capture probes 906, and be captured by the capture probes 906.
  • the separation distance 907 between first and second substrates is maintained between 2 microns and 1 mm (e.g., between 2 microns and 800 microns, between 2 microns and 700 microns, between 2 microns and 600 microns, between 2 microns and 500 microns, between 2 microns and 400 microns, between 2 microns and 300 microns, between 2 microns and 200 microns, between 2 microns and 100 microns, between 2 microns and 25 microns, between 2 microns and 10 microns), measured in a direction orthogonal to the surface of first substrate that supports sample.
  • the separation distance 907 between first and second substrates is less than 50 microns.
  • the distance is 2 microns. In some instances, the distance is 2.5 microns. In some instances, the distance is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 microns.
  • second substrate is placed in direct contact with the sample on the first substrate ensuring no diffusive spatial resolution losses. In some embodiments, the separation distance is measured in a direction orthogonal to a surface of the first substrate that supports the biological sample.
  • the sandwiching process may be facilitated by a device, sample holder, sample handling apparatus, or system described in, e.g., US. Patent Application Pub. No. 20210189475, PCT/US2021/036788, or PCT/US2021/050931.
  • the first and second substrates are placed in a substrate holder (e.g., an array alignment device) configured to align the biological sample and the array.
  • the device comprises a sample holder.
  • the sample holder includes a first member and a second member that receive a first substrate and a second substrate, respectively.
  • the device can include an alignment mechanism that is connected to at least one of the members and aligns the first and second members.
  • the devices of the disclosure can advantageously align the first substrate and the second substrate and any samples, barcoded probes, or permeabilization reagents that may be on the surface of the first and second substrates.
  • the sandwiching process comprises: mounting the first substrate on a first member of a support device, the first member configured to retain the first substrate; mounting the second substrate on a second member of the support device, the second member configured to retain the second substrate, applying a reagent medium to the first substrate and/or the second substrate, the reagent medium comprising a permeabilization agent, operating an alignment mechanism of the support device to move the first member and/or the second member such that a portion of the biological sample is aligned (e.g., vertically aligned) with a portion of the array of capture probes and within a threshold distance of the array of capture probes, and such that the portion of the biological sample and the capture probe contact the reagent medium, where the permeabilization agent releases the analyte from the biological sample.
  • a portion of the biological sample is aligned (e.g., vertically aligned) with a portion of the array of capture probes and within a threshold distance of the array of capture probes, and such that the portion of the biological sample and
  • the sample holder can include a first member including a first retaining mechanism configured to retain a first substrate comprising a sample.
  • the first retaining mechanism can be configured to retain the first substrate disposed in a first plane.
  • the sample holder can further include a second member including a second retaining mechanism configured to retain a second substrate disposed in a second plane.
  • the sample holder can further include an alignment mechanism connected to one or both of the first member and the second member.
  • the alignment mechanism can be configured to align the first and second members along the first plane and/or the second plane such that the sample contacts at least a portion of the reagent medium when the first and second members are aligned and within a threshold distance along an axis orthogonal to the second plane.
  • the alignment mechanism may be configured to move the second member along the axis orthogonal to the second plane and/or move the first member along an axis orthogonal to the first plane.
  • the alignment mechanism includes a linear actuator.
  • the alignment mechanism includes one or more of a moving plate, a bushing, a shoulder screw, a motor bracket, and a linear actuator.
  • the moving plate may be coupled to the first member or the second member.
  • the alignment mechanism may, in some cases, include a first moving plate coupled to the first member and a second moving plate coupled to the second member.
  • the linear actuator is configured to move the second member along an axis orthogonal to the plane of the first member and/or the second member.
  • the moving plate may be coupled to the second member and adjust the separation distance along a z axis (e.g., orthogonal to the second substrate) by moving the moving plate up in a superior direction toward the first substrate.
  • the linear actuator is configured to move the first member along an axis orthogonal to the plane of the first member and/or the second member.
  • the movement of the moving plate may be accomplished by the linear actuator configured to move the first member and/or the second member at a velocity.
  • the velocity may be controlled by a controller communicatively coupled to the linear actuator.
  • the linear actuator is configured to move the first member, the second member, or both the first member and the second member at a velocity of at least 0.1 mm/sec (e.g., at least 0.1 mm/sec to 2 mm/sec). In some aspects, the velocity may be selected to reduce or minimize bubble generation or trapping within the reagent medium. In some embodiments, the linear actuator is configured to move the first member, the second member, or both the first member and the second member with an amount of force of at least 0.1 lbs (e.g., between 0.1-4.0 pounds of force).
  • the velocity of the moving plate may affect bubble generation or trapping within the reagent medium. It may be advantageous to minimize bubble generation or trapping within the reagent medium during the “sandwiching” process, as bubbles can interfere with the migration of analytes through the reagent medium to the array.
  • the closing speed is selected to minimize bubble generation or trapping within the reagent medium. In some embodiments, the closing speed is selected to reduce the time it takes the flow front of the reagent medium from an initial point of contact with the first and second substrate to sweep across the sandwich area (also referred to herein as “closing time”).
  • the closing speed is selected to reduce the closing time to less than about 1100 milliseconds (ms). In some embodiments, the closing speed is selected to reduce the closing time to less than about 1000 ms. In some embodiments, the closing speed is selected to reduce the closing time to less than about 900 ms. In some embodiments, the closing speed is selected to reduce the closing time to less than about 750 ms. In some embodiments, the closing speed is selected to reduce the closing time to less than about 600 ms. In some embodiments, the closing speed is selected to reduce the closing time to about 550 ms or less. In some embodiments, the closing speed is selected to reduce the closing time to about 370 ms or less.
  • the closing speed is selected to reduce the closing time to about 200 ms or less. In some embodiments, the closing speed is selected to reduce the closing time to about 150 ms or less.
  • Analytes within a biological sample may be released through disruption (e.g., permeabilization, digestion, etc.) of the biological sample or may be released without disruption.
  • permeabilizing e.g., any of the permeabilization reagents and/or conditions described herein
  • a biological sample are described herein, including for example including the use of various detergents, buffers, proteases, and/or nucleases for different periods of time and at various temperatures.
  • various methods of delivering fluids e.g., a buffer, a permeabilization solution
  • a substrate holder e.g., for sandwich assembly, sandwich configuration, as described herein
  • the sandwich configuration described herein between a first substrate comprising a biological sample (e.g., slide 903) and a second substrate comprising a spatially barcoded array (e.g., slide 904 with barcoded capture probes 906) may include a reagent medium (e.g., a liquid reagent medium, e.g., a permeabilization solution 905 or other target molecule release and capture solution) to fill a gap (e.g., gap 907). It may be desirable that the reagent medium be free from air bubbles between the slides to facilitate transfer of target molecules with spatial information. Additionally, air bubbles present between the slides may obscure at least a portion of an image capture of a desired region of interest. Accordingly, it may be desirable to ensure or encourage suppression and/or elimination of air bubbles between the two substrates (e.g., slide 903 and slide 904) during a permeabilization step.
  • a reagent medium e.g., a liquid reagent medium, e.g., a
  • Workflows described herein may include contacting a drop of the reagent medium (e.g., liquid reagent medium, e.g., a permeabilization solution 905) disposed on a first substrate or a second substrate with at least a portion of the second substrate or first substrate, respectively.
  • the contacting comprises bringing the two substrates into proximity such that the sample on the first substrate is aligned with the barcode array of capture probes on the second substrate.
  • the drop includes permeabilization reagents (e.g., any of the permeabilization reagents described herein).
  • the rate of permeabilization of the biological sample is modulated by delivering the permeabilization reagents (e.g., a fluid containing permeabilization reagents) at various temperatures.
  • the reagent medium e.g., liquid reagent medium, permeabilization solution 905 may fill a gap (e.g., the gap 907) between a first substrate (e.g., slide 903) and a second substrate (e.g., slide 904 with barcoded capture probes 906) to warrant or enable transfer of target molecules with spatial information.
  • a gap e.g., the gap 907 between a first substrate (e.g., slide 903) and a second substrate (e.g., slide 904 with barcoded capture probes 906) to warrant or enable transfer of target molecules with spatial information.
  • Described herein are examples of filling methods that may suppress bubble formation and suppress undesirable flow of transcripts and/or target molecules or analytes.
  • Robust fluidics in the sandwich making described herein may preserve spatial information by reducing or preventing deflection of molecules as they move from the tissue slide to the capture slide.
  • the reagent medium comprises a permeabilization agent.
  • Suitable agents for this purpose include, but are not limited to, organic solvents (e.g., acetone, ethanol, and methanol), cross-linking agents (e.g, paraformaldehyde), detergents (e.g, saponin, Triton X-100TM, Tween-20TM, or sodium dodecyl sulfate (SDS)), and enzymes (e.g., trypsin, proteases (e.g., proteinase K).
  • the detergent is an anionic detergent (e.g., SDS or N-lauroylsarcosine sodium salt solution).
  • Exemplary permeabilization reagents are described in in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the reagent medium comprises a lysis reagent.
  • Lysis solutions can include ionic surfactants such as, for example, sarkosyl and sodium dodecyl sulfate (SDS).
  • chemical lysis agents can include, without limitation, organic solvents, chelating agents, detergents, surfactants, and chaotropic agents. Exemplary lysis reagents are described in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the reagent medium comprises a protease.
  • proteases include, e.g., pepsin, trypsin, pepsin, elastase, and proteinase K. Exemplary proteases are described in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the reagent medium comprises a detergent. Exemplary detergents include sodium dodecyl sulfate (SDS), sarkosyl, saponin, Triton X-100TM, and Tween-20TM. Exemplary detergents are described in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the reagent medium comprises a nuclease.
  • the nuclease comprises am RNase.
  • the RNase is selected from RNase A, RNase C, RNase H, and RNase I.
  • the reagent medium comprises one or more of sodium dodecyl sulfate (SDS), proteinase K, pepsin, N- lauroylsarcosine, RNAse, and a sodium salt thereof.
  • SDS sodium dodecyl sulfate
  • the sample holder is compatible with a variety of different schemes for contacting the aligned portions of the biological sample and array with the reagent medium to promote analyte capture.
  • the reagent medium is deposited directly on the second substrate (e.g., forming a reagent medium that includes the permeabilization reagent and the feature array), and/or directly on the first substrate.
  • the reagent medium is deposited on the first and/or second substrate, and then the first and second substrates aligned in the sandwich configuration such that the reagent medium contacts the aligned portions of the biological sample and array.
  • the reagent medium is introduced into the gap 907 while the first and second substrates are aligned in the sandwich configuration.
  • a dried permeabilization reagent is applied or formed as a layer on the first substrate or the second substrate or both prior to contacting the sample and the feature array.
  • a reagent can be deposited in solution on the first substrate or the second substrate or both and then dried. Drying methods include, but are not limited to spin coating a thin solution of the reagent and then evaporating a solvent included in the reagent or the reagent itself.
  • the reagent can be applied in dried form directly onto the first substrate or the second substrate or both.
  • the coating process can be done in advance of the analytical workflow and the first substrate and the second substrate can be stored pre-coated.
  • the coating process can be done as part of the analytical workflow.
  • the reagent is a permeabilization reagent.
  • the reagent is a permeabilization enzyme, a buffer, a detergent, or any combination thereof.
  • the permeabilization enzyme is pepsin.
  • the reagent is a dried reagent (e.g., a reagent free from moisture or liquid).
  • the substrate that includes the sample e.g., a histological tissue section
  • the sample can be hydrated by contacting the sample with a reagent medium, e.g., a buffer that does not include a permeabilization reagent.
  • the hydration is performed while the first and second substrates are aligned in a sandwich configuration.
  • the aligned portions of the biological sample and the array are in contact with the reagent medium 905 for about 1 minute. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium 905 for about 5 minutes. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium 905 in the gap 907 for about 1 minute, about 5 minutes, about 10 minutes, about 12 minutes, about 15 minutes, about 18 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 36 minutes, about 45 minutes, or about an hour. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium 905 for about 1-60 minutes. In some instances, the aligned portions of the biological sample and the array are in contact with the reagent medium 905 for about 30 minutes.
  • the permeabilization agent can be removed from contact with sample (e.g., by opening sample holder) before complete permeabilization of sample.
  • sample e.g., by opening sample holder
  • the reduced amount of analyte captured and available for detection can be offset by the reduction in lateral diffusion that results from incomplete permeabilization of sample.
  • the spatial resolution of the assay is determined by the extent of analyte diffusion in the transverse direction (i.e., orthogonal to the normal direction to the surface of sample).
  • the device is configured to control a temperature of the first and second substrates.
  • the temperature of the first and second members is lowered to a first temperature that is below room temperature (e.g., 25 degrees Celsius) (e.g., 20 degrees Celsius or lower, 15 degrees Celsius or lower, 10 degrees Celsius or lower, 5 degrees Celsius or lower, 4 degrees Celsius or lower, 3 degrees Celsius or lower, 2 degrees Celsius or lower, 1 degree Celsius or lower, 0 degrees Celsius or lower, -1 degrees Celsius or lower, -5 degrees Celsius or lower).
  • the device includes a temperature control system (e.g., heating and cooling conducting coils) to control the temperature of the sample holder.
  • the temperature of the sample holder is controlled externally (e.g., via refrigeration or a hotplate).
  • the second member, set to or at the first temperature contacts the first substrate, and the first member, set to or at the first temperature, contacts the second substrate, thereby lowering the temperature of the first substrate and the second substrate to a second temperature.
  • the second temperature is equivalent to the first temperature.
  • the first temperature is lower than room temperature (e.g., 25 degrees Celsius).
  • the second temperature ranges from about -10 degrees Celsius to about 4 degrees Celsius.
  • the second temperature is below room temperature (e.g, 25 degrees Celsius) (e.g, 20 degrees Celsius or lower, 15 degrees Celsius or lower, 10 degrees Celsius or lower, 5 degrees Celsius or lower, 4 degrees Celsius or lower, 3 degrees Celsius or lower, 2 degrees Celsius or lower, 1 degree Celsius or lower, 0 degrees Celsius or lower, -1 degrees Celsius or lower, -5 degrees Celsius or lower).
  • room temperature e.g, 25 degrees Celsius
  • 20 degrees Celsius or lower e.g, 15 degrees Celsius or lower, 10 degrees Celsius or lower, 5 degrees Celsius or lower, 4 degrees Celsius or lower, 3 degrees Celsius or lower, 2 degrees Celsius or lower, 1 degree Celsius or lower, 0 degrees Celsius or lower, -1 degrees Celsius or lower, -5 degrees Celsius or lower.
  • the second substrate is contacted with the permeabilization reagent.
  • the permeabilization reagent is dried.
  • the permeabilization reagent is a gel or a liquid.
  • the biological sample is contacted with buffer. Both the first and second substrates are placed at lower temperature to slow down diffusion and permeabilization efficiency.
  • the sample can be contacted directly with a liquid permeabilization reagent without inducing an unwanted initiation of permeabilization due to the substrates being at the second temperature.
  • the low temperature slows down or prevents the initiation of permeabilization.
  • a second step keeping the sample holder and substrates at a cold temperature (e.g., at the first or second temperatures) continues to slow down or prevent the permeabilization of the sample.
  • the sample holder (and consequently the first and second substrates) is heated up to initiate permeabilization.
  • the sample holder is heated up to a third temperature.
  • the third temperature is above room temperature (e.g., 25 degrees Celsius) (e.g., 30 degrees Celsius or higher, 35 degrees Celsius or higher, 40 degrees Celsius or higher, 50 degrees Celsius or higher, 60 degrees Celsius or higher).
  • analytes that are released from the permeabilized tissue of the sample diffuse to the surface of the second substrate and are captured on the array (e.g., barcoded probes) of the second substrate.
  • the first substrate and the second substrate are separated (e.g., pulled apart) and temperature control is stopped.
  • a permeabilization solution can be introduced into some or all of the wells, and then the sample and the feature array can be contacted by closing the sample holder to permeabilize the sample.
  • a permeabilization solution can be soaked into a hydrogel film that is applied directly to the sample, and/or soaked into features (e.g., beads) of the array. When the first and second substrates are aligned in the sandwich configuration, the permeabilization solution promotes migration of analytes from the sample to the array.
  • different permeabilization agents or different concentrations of permeabilization agents can be infused into array features (e.g., beads) or into a hydrogel layer as described above.
  • array features e.g., beads
  • hydrogel layer e.g., a hydrogel layer
  • first and second substrates can include a conductive epoxy. Electrical wires from a power supply can connect to the conductive epoxy, thereby allowing a user to apply a current and generate an electric field between the first and second substrates.
  • electrophoretic migration results in higher analyte capture efficiency and better spatial fidelity of captured analytes (e.g., on a feature array) than random diffusion onto matched substrates without the application of an electric field (e.g., via manual alignment of the two substrates).
  • Exemplary methods of electrophoretic migration are described in WO 2020/176788, including at FIGs. 13-15, 24A-24B, and 25A-25C, which is hereby incorporated by reference in its entirety.
  • Loss of spatial resolution can occur when analytes migrate from the sample to the feature array and a component of diffusive migration occurs in the transverse (e.g., lateral) direction, approximately parallel to the surface of the first substrate on which the sample is mounted.
  • a permeabilization agent deposited on or infused into a material with anisotropic diffusion can be applied to the sample or to the feature array.
  • the first and second substrates are aligned by the sample holder and brought into contact.
  • a permeabilization layer that includes a permeabilization solution infused into an anisotropic material is positioned on the second substrate.
  • the feature array can be constructed atop a hydrogel layer infused with a permeabilization agent.
  • the hydrogel layer can be mounted on the second substrate, or alternatively, the hydrogel layer itself may function as the second substrate.
  • the permeabilization agent diffuses out of the hydrogel layer and through or around the feature array to reach the sample. Analytes from the sample migrate to the feature array. Direct contact between the feature array and the sample helps to reduce lateral diffusion of the analytes, mitigating spatial resolution loss that would occur if the diffusive path of the analytes was longer.
  • Spatial analysis workflows can include a sandwiching process described herein, e.g., a process as described in FIG. 9.
  • the workflow includes provision of the first substrate comprising the biological sample.
  • the workflow includes, mounting the biological sample onto the first substrate.
  • the workflow includes sectioning of the tissue sample (e.g., cryostat sectioning).
  • the workflow includes a fixation step.
  • the fixation step can include fixation with methanol.
  • the fixation step includes formalin (e.g., 2% formalin).
  • the biological sample on the first substrate is stained using any of the methods described herein.
  • the biological sample is imaged, capturing the stain pattern created during the stain step.
  • the biological sample then is destained prior to the sandwiching process.
  • the biological sample can be stained using known staining techniques, including, without limitation, Can-Grunwald, Giemsa, hematoxylin and eosin (H&E), hematoxylin, Jenner’s, Leishman, Masson’s trichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright’s, and/or Periodic Acid Schiff (PAS) staining techniques.
  • PAS staining is typically performed after formalin or acetone fixation.
  • the biological sample can be stained using a detectable label (e.g., radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes) as described elsewhere herein.
  • a biological sample is stained using only one type of stain or one technique.
  • staining includes biological staining techniques such as H&E staining.
  • staining includes biological staining using hematoxylin.
  • staining includes identifying analytes using fluorescently-conjugated antibodies, e.g., by immunofluorescence.
  • a biological sample is stained using two or more different types of stains, or two or more different staining techniques.
  • a biological sample can be prepared by staining and imaging using one technique (e.g., H&E staining and brightfield imaging), followed by staining and imaging using another technique (e.g., IHC/IF staining and fluorescence microscopy) for the same biological sample.
  • one technique e.g., H&E staining and brightfield imaging
  • another technique e.g., IHC/IF staining and fluorescence microscopy
  • methods for immunofluorescence include a blocking step.
  • the blocking step can include the use of blocking probes to decrease unspecific binding of the antibodies.
  • the blocking step can optionally further include contacting the biological sample with a detergent.
  • the detergent can include Triton X-100TM.
  • the method can further include an antibody incubation step.
  • the antibody incubation step effects selective binding of the antibody to antigens of interest in the biological sample.
  • the antibody is conjugated to an oligonucleotide (e.g., an oligonucleotide-antibody conjugate as described herein). In some embodiments, the antibody is not conjugated to an oligonucleotide.
  • the method further comprises an antibody staining step.
  • the antibody staining step can include a direct method of immunostaining in which a labelled antibody binds directly to the analyte being stained for.
  • the antibody staining step can include an indirect method of immunostaining in which a first antibody binds to the analyte being stained for, and a second, labelled antibody binds to the first antibody.
  • the antibody staining step is performed prior to sandwich assembly. In some embodiments where an oligonucleotide-antibody conjugate is used in the antibody incubation step, the method does not comprise an antibody staining step.
  • the methods include imaging the biological sample. In some instances, imaging occurs prior to sandwich assembly. In some instances, imaging occurs while the sandwich configuration is assembled. In some instances, imaging occurs during permeabilization of the biological sample. In some instances, images are captured using high resolution techniques (e.g., having 300 dots per square inch (dpi) or greater). For example, images can be captured using brightfield imaging (e.g., in the setting of hematoxylin or H&E stain), or using fluorescence microscopy to detect adhered labels. In some instances, high resolution images are captured temporally using e.g., confocal microscopy. In some instances, a low resolution image is captured.
  • high resolution techniques e.g., having 300 dots per square inch (dpi) or greater.
  • images can be captured using brightfield imaging (e.g., in the setting of hematoxylin or H&E stain), or using fluorescence microscopy to detect adhered labels.
  • high resolution images are captured temporally using e.g.,
  • a low resolution image (e.g., images that are about 72dpi and normally have an RGB color setting) can be captured at any point of the workflow, including but not limited to staining, destaining, permeabilization, sandwich assembly, and migration of the analytes. In some instances, a low resolution image is taken during permeabilization of the biological sample. [00253] In some embodiments, the location of the one or more analytes in a biological sample are determined by immunofluorescence.
  • one or more detectable labels bind to the one or more analytes that are captured (hybridized to) by a probe on the first slide and the location of the one or more analytes is determined by detecting the labels under suitable conditions.
  • one or more fluorophore-labeled antibodies are used to conjugate to a moiety that associates with a probe on the first slide or the analyte that is hybridized to the probe on the first slide.
  • the location(s) of the one or more analytes is determined by imaging the fluorophore-labeled antibodies when the fluorophores are excited by a light of a suitable wavelength.
  • the location of the one or more analytes in the biological sample is determined by correlating the immunofluorescence data to an image of the biological sample.
  • the tissue is imaged throughout the permeabilization step.
  • the biological samples can be destained.
  • destaining occurs prior to permeabilization of the biological sample.
  • H&E staining can be destained by washing the sample in HC1.
  • the hematoxylin of the H&E stain is destained by washing the sample in HC1.
  • destaining can include 1, 2, 3, or more washes in HC1.
  • destaining can include adding HC1 to a downstream solution (e.g., permeabilization solution).
  • the methods can include a wash step (e.g., with SSC (e.g., O. lx SSC)). Wash steps can be performed once or multiple times (e.g., lx, 2x, 3x, between steps disclosed herein). In some instances, wash steps are performed for about 10 seconds, about 15 seconds, about 20 seconds, about 30 seconds, or about a minute. In some instances, three washes occur for 20 seconds each. In some instances, the wash step occurs before staining the sample, after destaining the sample, before permeabilization the sample, after permeabilization the sample, or any combination thereof.
  • SSC e.g., O. lx SSC
  • Wash steps can be performed once or multiple times (e.g., lx, 2x, 3x, between steps disclosed herein). In some instances, wash steps are performed for about 10 seconds, about 15 seconds, about 20 seconds, about 30 seconds, or about a minute. In some instances, three washes occur for 20 seconds each. In some instances, the wash step occurs before
  • the first substrate and the second substrate are separated (e.g., such that they are no longer aligned in a sandwich configuration, also referred to herein as opening the sandwich).
  • subsequent analysis e.g., cDNA synthesis, library preparation, and sequences
  • the process of transferring the ligation product or methylated- adaptor-containing nucleic acid from the first substrate to the second substrate is referred to interchangeably herein as a “sandwich process,” “sandwiching process,” or “sandwiching”.
  • the sandwich process is further described in PCT Patent Application Publication No. WO 2020/123320, PCT/US2021/036788, and PCT/US2021/050931, which are incorporated by reference in its entirety.
  • This disclosure also provides methods, compositions, devices, and systems for using a single capture probe-containing to detect analytes from different biological samples (e.g., tissues) on different slides using serial sandwich processes.
  • a single capture probe-containing array is necessary for the methods disclosed herein.
  • analytes from different samples or tissues can be captured serially and demultiplexed by sample-specific index sequences.
  • the methods include generating a connected probe (e.g., a ligation product) in multiple biological samples (i.e.., a first sample, a second sample, a third sample, etc.).
  • Generation of a connected probe e.g., a ligation product
  • a connected probe e.g., a ligation product
  • analytes that are either protein analytes or nucleic acid (i.e., mRNA) analytes.
  • the multiplexed sandwich maker methods disclosed herein can be used to detect protein analytes.
  • the multiplexed sandwich maker methods disclosed herein can be used to detect nucleic acid (i.e., mRNA) analytes.
  • the methods, compositions, devices, and systems include utilizing an analyte capture agent in multiple biological samples (e.g., a first sample, a second sample, a third sample, etc.).
  • analyte capture agents for spatial detection has been described above, and the same methods are used herein to use an analyte capture agent to identify analytes in a biological sample.
  • the multiplexed sandwich maker methods disclosed herein can be used to detect protein analytes.
  • each connected probe e.g., a ligation product
  • analyte capture agent includes a sample index sequence, which is a nucleotide sequence that is associated with a particular sample of origin in the multiplex sandwich methods.
  • each sample is serially sandwiched to an array or slide having a plurality of capture probes that can detect and hybridize to a capture probe binding domain from the connected probe (e.g., a ligation product) or analyte capture agent.
  • the indexed connected probe or analyte capture agent actively or passively migrates from the sample to the array for capture by a capture probe.
  • the sandwich is opened, and the next sample is sandwiched with the array.
  • the array is washed prior to sandwiching with the next sample.
  • Additional samples or tissues e.g., 2 or more
  • connected probes e.g., ligation products
  • analyte capture agents from the additional samples or tissues can be transferred to the array in a similar manner. Because each sample includes a unique sample index, the sample of origin for each connected probe (e.g., a ligation product) or analyte capture agent that is captured on the array can be identified. In addition, the location of the connected probe (e.g., a ligation product) can be identified.
  • the location of the analyte capture agent can be identified.
  • the location is identified using fiducial markers on the gene expression slide (e.g., array) so that location of the ligation probe on the array mirrors the location of the sample on the sample slide.
  • fiducial markers are described in PCT Patent Application Publication No. WO 2020/123320, which is incorporated by reference in its entirety.
  • the biological sample is a formalin-fixed, paraffin-embedded (FFPE) sample, a frozen sample, or a fresh sample.
  • the biological sample is contacted with one or more stains.
  • the one or more stains include hematoxylin and eosin.
  • cell markers are detected using methods known in the art (e.g., using one or more optical labels such as fluorescent labels, radioactive labels, chemiluminescent labels, calorimetric labels, or colorimetric labels.
  • the biological sample is imaged before generating a connected probe (e.g., a ligation product) and before transferring the connected probe (e.g., a ligation product) to the gene expression slide.
  • the multiplex sandwich methods, compositions, devices, and systems described herein allow for detection of different types of samples and different analytes.
  • the samples used in the multiplex sandwich methods are from different species.
  • the samples used in the multiplex sandwich methods are from the same species but different individuals in the same species.
  • the samples used in the multiplex sandwich methods are from the same individual organism.
  • the samples are from different tissues or cell types.
  • the samples are from the same tissues or cell types.
  • the samples are from the same subject taken at different time points (e.g., before and after treatment). It is appreciated that the samples can be from any source so long as ligated products having sample index sequences unique to each sample are generated.
  • samples can be used in the methods described herein. For example, in some instances, at least two samples are used. In some instances, more than two samples (e.g., at least 3, 4, 5, 6, 7, 8, 9, 10, or more) samples are used in the methods disclosed herein. It is appreciated that each sample can be from different sources (e.g., different species, different organisms). In some embodiments, from each sample, the same gene is detected and identified. In some embodiments, for each sample, different genes are detected and identified.
  • probe oligonucleotide for each sample in a multiplexed setting can include one or more unique sequences to identify the origin of the connected probe (e.g., a ligation product).
  • the unique sequence is a sample index sequence.
  • probe oligonucleotides for each sample include one or more (e.g., at least 1, 2, 3, 4, 5, or more) unique sample index sequence to identify the origin of the connected probe (e.g., a ligation product).
  • the sample index is about 5 nucleotides to about 50 nucleotides long (e.g., about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides long.
  • the sample index is about 5-15 nucleotides long.
  • the sample index is about 10-12 nucleotides long. Both synthetic and/or naturally-occurring nucleotides can be used to generate a sample index sequence. It is appreciated that any sequence can be designed so long as it is unique among other sample index sequences and optionally that it can be distinguished from any sequence in the genome of the sample.
  • a sample index sequence can be located anywhere on the connected probe (e.g., a ligation product) so long as it does not affect (1) hybridization of the probe oligonucleotides to the analyte, (2) ligation of the probe oligonucleotides to generate the connected probe (e.g, a ligation product), and (3) hybridization of the capture probe binding domain to the capture probe on an array.
  • the sample index sequence can be located on the first probe oligonucleotide (e.g, the left hand probe; i.e., as shown in FIG. 6A-B).
  • the sample index is located on the flap of the first probe oligonucleotide that does not hybridize to the analyte.
  • the sample index sequence can be located on the second probe oligonucleotide (e.g., the right hand probe; i.e., as shown in FIG. 6A-B).
  • the sample index is located on the flap of the second probe oligonucleotide that does not hybridize to the analyte.
  • FIG. 10 illustrates a block diagram illustrating an exemplary, non-limiting system 1000 for quantifying spatial analyte data for a plurality of analytes of a first species in accordance with some embodiments.
  • the system 1000 includes one or more processing units CPU(s) 1002 (also referred to as processors), one or more network interfaces 1004, a user interface 1006, a memory 1012, and one or more communication buses 1014 for interconnecting these components.
  • the communication buses 1014 optionally include circuitry (sometimes called a chipset) that interconnects and controls communications between system components.
  • the memory 1012 typically includes high-speed random access memory, such as DRAM, SRAM, DDR RAM, ROM, EEPROM, flash memory, CD-ROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, other random access solid state memory devices, or any other medium which can be used to store desired information; and optionally includes non-volatile memory, such as one or more magnetic disk storage devices, optical disk storage devices, flash memory devices, or other non-volatile solid state storage devices.
  • the memory 1012 optionally includes one or more storage devices remotely located from the CPU(s) 1002.
  • the memory 1012, or alternatively the non-volatile memory device(s) within the memory 1012 comprises a non- transitory computer readable storage medium. It will be appreciated that this memory 1012 can be distributed across one or more computers.
  • the memory 1012 or alternatively the non-transitory computer readable storage medium stores the following programs, modules and data structures, or a subset thereof:
  • an optional operating system 1016 that includes procedures for handling various basic system services and for performing hardware dependent tasks;
  • a normalization module 1020 for obtaining normalized counts for respective analyte capture agents
  • a feature data construct 1021 comprising electronic representation of one or more features 1022 (e.g., 1022-1, 1022-2, ...1022-M) (e.g., spatially barcoded features) on a substrate, a respective electronic representation of a feature 1022 including: o respective raw counts 1024 of one or more respective analyte capture agents whose oligonucleotide hybridized to the respective feature 1022.
  • feature 1 includes a raw count 1024-1- 1 of analyte capture agent 1-1, . . ., and a raw count 1024-1-Q of analyte capture agent 1-Q, where Q is a positive integer of 2 or greater.
  • Feature 2 includes a raw count 1024-2- 1 of analyte capture agent 2- 1, and a raw count 1024-2-Q of analyte capture agent 2-Q, where Q is a positive integer of 2 or greater; o respective normalized counts 1026 of the one or more respective analyte capture agents whose oligonucleotide hybridized to the respective feature 1022.
  • feature 1 includes a normalized count 1026-1-1 of analyte capture agent 1-1, . . ., a normalized count 1026 -1-Q of analyte capture agent 1-Q, where Q is a positive integer of 2 or greater.
  • Feature 2 includes a normalized count 1026-1- 1 of analyte capture agent 2-1, . .
  • a normalized count 1026-2-Q of analyte capture agent 2-Q where Q is a positive integer of 2 or greater
  • a respective spatial barcode 1028 e.g., 1028-1, 1028-2, . . . 1028-M, where M is a positive integer of 2 or greater, that spatially identifies the spatially barcoded feature on the substrate.
  • the user interface 1006 includes an input device (e.g., a keyboard, a mouse, a touchpad, a track pad, and/or a touch screen) 1010 for a user to interact with the system 1000 and a display 1008.
  • an input device e.g., a keyboard, a mouse, a touchpad, a track pad, and/or a touch screen
  • one or more of the above identified elements are stored in one or more of the previously mentioned memory devices and correspond to a set of instructions for performing a function described above.
  • the above identified modules or programs (e.g., sets of instructions) need not be implemented as separate software programs, procedures or modules, and thus various subsets of these modules may be combined or otherwise re-arranged in various implementations.
  • the memory 1012 optionally stores a subset of the modules and data structures identified above. Furthermore, in some embodiments, the memory stores additional modules and data structures not described above.
  • one or more of the above identified elements is stored in a computer system, other than that of system 1000, that is addressable by system 1000 so that system 1000 may retrieve all or a portion of such data when needed.
  • FIG. 10 shows an exemplary system 1000, the figure is intended more as functional description of the various features that may be present in computer systems than as a structural schematic of the implementations described herein. In practice, and as recognized by those of ordinary skill in the art, items shown separately could be combined and some items could be separated. [00274] (g) Methods for Normalization
  • FIGS. 11 A, 11B, 11C, 11D, HE, HF, 11G, HH, HI, HJ, 11K, and HL collectively illustrate a method 1100 for quantifying spatial analyte data for a plurality of analytes, in accordance with some embodiments.
  • the plurality of analytes is in a biological sample.
  • the biological sample is of a first species (e.g., human, dog, cat, mouse, rat, etc.).
  • the biological sample is of mammal, a bird, a reptile, an amphibian, a fish, an insect, an arachnid, a mollusk, a crustacean, or a plant.
  • the plurality of analytes comprises five or more analytes, ten or more analytes, fifty or more analytes, one hundred or more analytes, five hundred or more analytes, 1000 or more analytes, 2000 or more analytes, or between 2000 and 100,000 analytes.
  • the plurality of analytes comprises DNA, RNA, proteins, or a combination thereof.
  • each respective analyte in the plurality of analytes is the same type of analyte.
  • the plurality of analytes includes at least an analyte of a first type (e.g., nucleic acids, such as DNA or RNA ) and an analyte of a second type (e.g., protein).
  • the plurality of analytes comprises a plurality of analyte types (e.g., RNA and protein, RNA and DNA, DNA and protein, or a combination of RNA, DNA, and protein).
  • the plurality of analytes comprises at least 5, at least 10, at least 20, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 2000, at least 3000, at least 5000, at least 6000, at least 7000, at least 8000, at least 9000, at least 10,000, at least 20,000, at least 30,000, at least 40,000, at least 50,000, at least 100,000, at least 200,000, or at least 300,000 analytes.
  • the plurality of analytes comprises no more than 500,000, no more than 200,000, no more than 100,000, no more than 80,000, no more than 50,000, no more than 30,000, no more than 20,000, no more than 10,000, no more than 5000, no more than 3000, no more than 2000, no more than 1000, no more than 500, no more than 100, or no more than 50 analytes. In some embodiments, the plurality of analytes comprises between 5 and 2000, between 1000 and 100,000, between 2000 and 10,000, between 5000 and 50,000, between 50 and 5000, or between 100 and 10,000 analytes. In some embodiments, the plurality of analytes falls within another range starting no lower than 5 analytes and ending no higher than 500,000 analytes.
  • the method 1100 includes exposing a plurality of analyte capture agents to a biological sample from a subject that is a member of the first species.
  • the first species is human.
  • the first species is a mammalian species.
  • the first species is a plant species.
  • the biological sample is of mammal, a bird, a reptile, an amphibian, a fish, an insect, an arachnid, a mollusk, a crustacean, or a plant.
  • the exposing of the plurality of analyte capture agents to a biological sample is done under conditions that (i) cause at least a first subset of the plurality of analyte capture agents to specifically bind to a first subset of analytes in the plurality of analytes in the biological sample, and (ii) cause at least a second subset of the plurality of analyte capture agents to non-specifically associate with the biological sample.
  • the second subset of the plurality of analyte capture agents non-specifically associate with the biological sample because the analyte capture agents comprise antibodies (or antigen binding fragments thereof) raised on antigens from one or more species other than the first species (of the biological sample).
  • the second subset of the plurality of analyte capture agents non-specifically associate with the biological sample by binding to one or more non-target analytes/antigens present in the biological sample.
  • signal derived using the second subset of the plurality of analyte capture agents is not antigen-specific and therefore represents nonspecific background.
  • the first subset of the plurality of analyte capture agents specifically bind to the first subset of analytes in the biological sample because the analyte capture agents comprise antibodies (or antigen binding fragments thereof) raised on antigens from the same species as the biological sample.
  • the specific binding between an analyte capture agent and an analyte has a KD value of 1 picoMolar or smaller. In some embodiments, the specific binding between an analyte capture agent and an analyte has a KD value of 1 x IO' 10 molar or smaller under conditions (e.g., buffer, salt, and temperature) that facilitate binding between antibodies and antigens. In some embodiments, the specific binding between an analyte capture agent and an analyte has a K value of 1 x 10' 9 molar or smaller under conditions that facilitate binding between antibodies and antigens.
  • the specific binding between an analyte capture agent and an analyte has a KD value of 1 x 10' 8 molar or smaller under conditions that facilitate binding between antibodies and antigens. In some embodiments, the specific binding between an analyte capture agent and an analyte has a KD value of 1 x 10' 7 molar or smaller under conditions that facilitate binding between antibodies and antigens. In some embodiments, the non-specific association of an analyte capture agent in the second subset of the plurality of analyte capture agents with the biological sample is characterized by a KD value of 1 x 10' 6 molar or greater under conditions that facilitate binding between antibodies and antigens.
  • the non-specific association of an analyte capture agent in the second subset of the plurality of analyte capture agents with the biological sample is characterized by a Ko value of 1 x 10' 5 molar or greater under conditions that facilitate binding between antibodies and antigens. In some embodiments, the non-specific association of an analyte capture agent in the second subset of the plurality of analyte capture agents with the biological sample is characterized by a Ko value of 1 x 10' 4 molar or greater under conditions that facilitate binding between antibodies and antigens.
  • the non-specific association of an analyte capture agent in the second subset of the plurality of analyte capture agents with the biological sample is characterized by a Ko value of 1 x 10' 3 molar or greater under conditions that facilitate binding between antibodies and antigens.
  • conditions that facilitate binding between antibodies and antigens are characterized by Darwish, 2006, “Immunoassay Methods and their Applications in Pharmaceutical Analysis: Basic Methodology and Recent Advances,” Int J. Biomed Sci 2(3), pp. 217-235; and Cox etal., Immunoassay Methods.
  • Each respective analyte capture agent in the first and second subsets of the plurality of analyte capture agents comprises a corresponding analyte binding moiety and a corresponding oligonucleotide comprising an analyte binding moiety barcode (e.g., a barcode that identifies that analyte binding moiety (e.g., an antibody)) and a capture handle sequence as disclosed herein.
  • an analyte binding moiety barcode e.g., a barcode that identifies that analyte binding moiety (e.g., an antibody)
  • a capture handle sequence as disclosed herein.
  • the biological sample is a sectioned tissue sample having a depth of 500 microns or less. In some embodiments, the biological sample is a sectioned tissue sample having a depth of 100 microns or less. In some embodiments, the sectioned tissue sample has a depth of 80 microns or less, 70 microns or less, 60 microns or less, 50 microns or less, 40 microns or less, 25 microns or less, 20 microns or less, 15 microns or less, 12 microns or less, 10 microns or less, 5 microns or less, 2 microns or less, or 1 micron or less.
  • the biological sample is a sectioned tissue sample having a depth of at least 0.1 microns, at least 1 micron, at least 5 microns, at least 10 microns, at least 12 microns, at least 15 microns, at least 20 microns, at least 30 microns, at least 50 microns, or at least 80 microns.
  • the sectioned tissue sample has a depth of between 10 microns and 20 microns, between 10 microns and 15 microns, between 1 and 10 microns, between 0.1 and 5 microns, between 20 and 100 microns, between 1 and 50 microns, or between 0.5 and 10 microns.
  • the sectioned tissue sample falls within a range starting no lower than 0.1 microns and ending no higher than 500 microns.
  • the biological sample is a fixed tissue sample.
  • Example details of suitable fixed tissue samples in accordance with some embodiments of the present disclosure are disclosed in section (c) “Capturing Analytes for Spatial Detection using Analyte Capture Agents.”
  • the fixed tissue sample is a formalin fixed paraffin embedded (FFPE) tissue sample.
  • FFPE formalin fixed paraffin embedded
  • the biological sample is a fresh frozen tissue sample.
  • each analyte in the first subset of analytes comprises a protein.
  • the protein is an intracellular or extracellular protein, optionally a cell surface protein. Suitable cell surface proteins include transmembrane proteins.
  • the first subset of the plurality of analyte capture agents comprises two, three, four, five, six, seven, eight, or nine or more antibodies (including antigen binding fragments thereof) that each bind to a different antigen selected from the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin (VIM), CD3 (e.g., CD3E), CD4, CD8A, CXCR5, CD45RA, CD45RO, CD40, CD19, CD20, PAX5, CD27, CCR7, CD21, CDl lc, CD68, CD163, CD14, CDl lb, HLA-DR, CD 16, CD66B, and CD 138, optionally where the antigen is a human antigen.
  • a different antigen selected from the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin (VIM), CD3 (e.g., CD3
  • the first subset of the plurality of analyte capture agents comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40 or more analyte capture agents each containing an antibody (including antigen binding fragments thereof) that each bind an antigen that is not selected from the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin (VIM), CD3 (e g, CD3E), CD4, CD8A, CXCR5, CD45RA, CD45RO, CD40, CD19, CD20, PAX5, CD27, CCR7, CD21, CDl lc, CD68, CD163, CD14, CDl lb, HLA-DR, CD 16, CD66B, and CD 138.
  • an antibody including antigen binding fragments thereof
  • none of the analyte capture agents in the first subset of the plurality of analyte capture agents bind an antigen in the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin, CD3, CD4, CD8A, CXCR5, CD45RA, CD45RO, CD40, CD19, CD20, PAX5, CD27, CCR7, CD21, CDl lc, CD68, CD163, CD14, CDllb, HLA-DR, CD16, CD66B, and CD138.
  • the first subset of the plurality of analyte capture agents comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 antibodies that each bind to a different antigen selected from the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin (VIM), CD3 (e.g., CD3E), CD4, CD8A, CXCR5, CD45RA, CD45RO, CD40, CD19, CD20, PAX5, CD27, CCR7, CD21, CDl lc, CD68, CD163, CD14, CDl lb, HLA-DR, CD 16, CD66B, and CD 138, optionally where the antigen is a human antigen.
  • a different antigen selected from the group consisting of alphaSMA, PanCK, EPCAM, CD31, PDL1, PD1, PCNA, BCL2, Vimentin (VIM), CD3 (e.g., CD3E), CD4,
  • FIG. 12A illustrates exemplary analyte binding moieties of the second subset of the plurality of analyte capture agents in accordance with one embodiment of the present disclosure (subset 1250).
  • FIG. 12A and FIG. 12B collectively illustrate exemplary analyte binding moieties of the first subset of the plurality of analyte capture agents and the respective analytes (e.g., proteins) bound thereby in accordance with one embodiment of the present disclosure (subset 1252).
  • the second subset of the plurality of analyte capture agents includes any 1, 2, 3, or all 4 of the analyte binding moieties of subset 1250.
  • the first subset of the plurality of analyte capture agents includes any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or all 31 of the analyte binding moieties of subset 1252.
  • FIG. 13 illustrates a list 1300 providing information of exemplary analyte capture agents in accordance with some embodiments of the present disclosure.
  • Each data row in the list 1300 corresponds to a respective analyte capture agent.
  • list 1300 includes a corresponding ID 1302, a name 1304 (e.g., of an analyte bound by the analyte binding moiety (e.g., antibody)), a sequencing primer 1306, feature type 1308 (in FIG.
  • a respective analyte capture agent is a false control (e.g., the entry for 1310 is FALSE) when its corresponding analyte binding moiety (e.g., antibody) is expected to bind (e.g., specifically) to a respective analyte in the biological sample (e.g., specific binding).
  • a respective analyte capture agent is a true control (e.g., a negative control, the entry for 1310 is TRUE) when its corresponding analyte binding moiety is not expected to bind specifically to the biological sample.
  • a true control may non-specifically bind to the biological sample.
  • the first subset of analyte capture agents consists of between 5 and 5000, between 5 and 2500, between 5 and 500, between 10 and 1000 or between 10 and 500 analyte capture agents.
  • the second subset of analyte capture agents consists of between 2 and 500, between 2 and 250, between 2 and 100, between 2 and 50, between 4 and 40, between 5 and 10, or between 2 and 25 analyte capture agents.
  • the method includes aligning the biological sample with a first substrate comprising an array, such that at least a portion of the biological sample is aligned with the array.
  • Suitable alignment methods are disclosed herein as well as in PCT Patent Publication No. W02022/140028 Al entitled “METHODS, COMPOSITIONS, AND SYSTEMS FOR CAPTURING PROBES AND/OR BARCODES”, published June 30, 2022 start here ; and (ii) PCT Patent publication No. W02023/044071 Al, entitled “Systems and Methods for Image Registration or Alignment” published March 23, 2023.
  • the array comprises at least 100, 200, 500, 1000, 2000, 3000, 4000, or 5000 spatially barcoded features. Further disclosure of example arrays is disclosed in the section entitled “Introduction” above.
  • an “array” refers to a specific arrangement of a plurality of spatially barcoded features, where the arrangement is either irregular or forms a regular pattern. Individual features in the array differ from one another based on their relative spatial locations. In general, at least two of the features in the array include a distinct capture probe (e.g., any of the examples of capture probes described herein). More disclosure on example arrays used in accordance with some embodiments of the present disclosure are disclosed in PCT Patent Publication No. W02023/044071, entitled “Systems and Methods for Image Registration or Alignment” published March 23, 2023.
  • Each spatially barcoded feature comprises a respective capture probe plurality.
  • Each capture probe in the respective capture probe plurality comprises: (i) a respective spatial barcode, in a plurality of spatial barcodes, that spatially identifies the spatially barcoded feature on the first substrate and (ii) a capture domain sequence. More disclosure on capture probes, and their spatial barcodes and capture domain sequences is provided in the section above entitled “Introduction.”
  • the analyte binding moiety of the respective analyte capture agent comprises an antibody that reacts with a respective analyte of the first subset of the plurality of analytes.
  • the corresponding antibody is conjugated to the corresponding oligonucleotide of the respective analyte capture agent.
  • the oligonucleotide of the respective analyte capture agent is also referred to herein as an analyte-binding moiety barcode domain 408.
  • FIG. 4 illustrates an analyte capture agent 402 comprised of an analyte-binding moiety 404 conjugated to a corresponding oligonucleotide (analyte-binding moiety barcode domain 408).
  • the analyte-binding moiety barcode domain (oligonucleotide) 408 can comprise an analyte binding moiety barcode and a capture handle sequence.
  • FIG. 5 illustrates how the analyte binding moiety 522 is conjugated by linker 520 to an analyte binding moiety barcode 516 and capture handle sequence 514.
  • the oligonucleotide conjugated to the analyte binding moiety 522 of the analyte capture agent 526 comprises the linker 520, an optional functional sequence 518, analyte binding moiety barcode 516, and capture handle sequence 514.
  • the corresponding capture handle sequence 514 of the corresponding oligonucleotide comprises a nucleic acid sequence that is substantially complementary to the capture domain sequence (in particular the capture domain sequence of capture domain 512) of a capture probe 524 in a respective capture probe plurality.
  • the analyte binding moiety of the second analyte capture agent comprises a control antibody reactive to an antigen of a second species.
  • the second species is other than the first species.
  • the control antibody is conjugated to the oligonucleotide of the second analyte capture agent.
  • the capture handle sequence of the oligonucleotide of the second analyte capture agent comprises a nucleic acid sequence that is substantially complementary to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • each analyte binding moiety of each respective analyte capture agent in the first subset of the plurality of analyte capture agents comprises an IgA, IgD, IgE, IgG, or IgM antibody (or a fragment thereof).
  • the respective analyte binding moiety of the respective analyte capture agent comprises an antibody that binds to a respective analyte of the first subset of the plurality of analytes.
  • the antibody is conjugated to the oligonucleotide of the respective analyte capture agent.
  • the capture handle sequence of the corresponding oligonucleotide comprises a nucleic acid sequence that is substantially complementary to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • the respective analyte binding moiety of the respective analyte capture agent comprises a control antibody reactive to an antigen of a species other than the first species.
  • the control antibody is conjugated to the oligonucleotide of the respective analyte capture agent.
  • the capture handle sequence of the oligonucleotide comprises a nucleic acid sequence that is complementary to a capture domain sequence of the capture probe in a respective capture probe plurality.
  • the first species is human and the second subset of the plurality of analyte capture agents collectively comprises analyte capture agents comprising control antibodies reactive to a non-human species, for example, an immunoglobulin from mouse, an immunoglobulin from rat, an immunoglobulin from rabbit, an immunoglobulin from dog, or a combination thereof.
  • the first species is human and the second subset of the plurality of analyte capture agents comprises a first analyte capture agent comprising an analyte binding moiety that was raised on an antigen from a second species, and a second analyte capture agent that was raised on an antigen from a third species, where the second species and the third species are not human and are different from each other.
  • the second species is a mammalian. In some such embodiments, both the second species and the third species are mammalian.
  • the first species is not human.
  • the first species is selected from mouse, rat, hamster, rabbit, dog, cat, sheep, goat, or horse
  • the second species is selected from mouse, rat, hamster, rabbit, dog, cat, sheep, goat, or horse, but is mutually exclusive to the first species.
  • the first species is human and the second subset of the plurality of analyte capture agents comprises a first analyte capture agent comprising a first control antibody reactive to mouse IgG2a, a second analyte capture agent comprising a second control antibody reactive to mouse IgGlk, a third analyte capture agent comprising a third control antibody reactive to mouse IgG2bk, and a fourth analyte capture agent comprising a fourth control antibody reactive to rat IgG2a.
  • a first analyte capture agent comprising a first control antibody reactive to mouse IgG2a
  • a second analyte capture agent comprising a second control antibody reactive to mouse IgGlk
  • a third analyte capture agent comprising a third control antibody reactive to mouse IgG2bk
  • a fourth analyte capture agent comprising a fourth control antibody reactive to rat IgG2a.
  • the capture domain sequence of one or more capture probes in one or more capture probe pluralities comprises a poly(T) sequence.
  • the poly(T) sequence consists of between two and one hundred contiguous thymine residues.
  • the poly(T) sequence comprises between two and one hundred contiguous thymine residues.
  • the poly(T) sequence consists of between three and fifty contiguous thymine residues.
  • the poly(T) sequence comprises between three and fifty contiguous thymine residues.
  • the poly(T) sequence consists of between three and twenty -five contiguous thymine residues.
  • the poly(T) sequence comprises between three and twenty-five contiguous thymine residues.
  • the capture probe 524 in one or more capture probe pluralities further comprises one or more functional domains (e.g., functional sequence 506 of FIG. 5), a unique molecular identifier (UMI), a cleavage domain 504, or a combination thereof.
  • functional domains e.g., functional sequence 506 of FIG. 5
  • UMI unique molecular identifier
  • cleavage domain 504 e.g., cleavage domain 504
  • a respective capture probe plurality includes 10 or more capture probes, 100 or more capture probes, 500 or more capture probes, 1000 or more capture probes, 2000 or more capture probes, 10,000 or more capture probes, 100,000 or more capture probes, 1 x 10 6 or more capture probes, 2 x 10 6 or more capture probes, or 5 x 10 6 or more capture probes.
  • each capture probe in a respective capture probe plurality includes the same spatial barcode from the plurality of spatial barcodes.
  • there is only one unique spatial barcode for a particular feature each capture probe in the feature has this spatial barcode, and no capture probe in any other feature in the array has this spatial barcode.
  • each capture probe in a respective capture probe plurality collectively includes two spatial barcodes from the plurality of spatial barcodes.
  • there are two unique spatial barcodes for a particular feature each capture probe in the feature has one of these two spatial barcodes, and no capture probe in any other feature in the array has either of these spatial barcodes.
  • each capture probe in a respective capture probe plurality collectively includes M spatial barcodes from the plurality of spatial barcodes, where M is 3, 4, 5, 6, 7, 8, 9, 10 or some other positive integer.
  • M is 3, 4, 5, 6, 7, 8, 9, 10 or some other positive integer.
  • there are M unique spatial barcodes for a particular feature each capture probe in the feature has one of these M spatial barcodes, and no capture probe in any other feature in the array has any of the M spatial barcodes.
  • each respective spatially barcoded feature in the array is contained within a 100 micron by 100 micron square on the first substrate.
  • a distance between a center of each respective spatially barcoded feature to a neighboring spatially barcoded feature in the array on the first substrate is between 10 microns and 100 microns.
  • a shape of each spatially barcoded feature in the array on the first substrate is a closed-form shape.
  • the closed-form shape is circular, elliptical, or an N-gon, where N is a value between 1 and 20.
  • the closed-form shape is circular and each spatially barcoded feature in the array has a diameter of 80 microns or less.
  • the closed-form shape is circular and each spatially barcoded feature in the array has a diameter of between 8 microns and 40 microns.
  • a distance between a center of each respective spatially barcoded feature to a neighboring spatially barcoded feature in the array on the first substrate is between 5 microns and 50 microns.
  • each respective spatially barcoded feature in the array is contained within a 10 micron by 10 micron square on a substrate. In some embodiments, the distance between a center of each respective spatially barcoded feature to a neighboring spatially barcoded feature in the array is between 2 microns and 10 microns. In some embodiments, the distance between a center of each respective spatially barcoded feature to a neighboring spatially barcoded feature in the array is between 4 microns and 8 microns. In some embodiments, the shape of each feature in the array is a closed-form shape. In some embodiments, the closed-form shape is circular and each feature in the array has a width of between 3 microns and 7 microns. In some embodiments, the closed-form shape is square and each feature in the array has a width of between 6 microns and 10 microns. In some embodiments, a feature is not visible by a human without magnification.
  • capture spots including but not limited to beads, bead arrays, bead properties (e.g., structure, materials, construction, cross-linking, degradation, reagents, and/or optical properties), synthesis and conjugation of capture probes to beads, and for covalently and non-covalently bonding beads to substrates are described in U.S. Patent Publication No. US20210062282, U.S. Patent Publication No. 20110059865A1, U.S. Patent No. 9,012,022, PCT Publication No.
  • a plurality of barcoded features as described herein includes a plurality of barcoded beads.
  • the plurality of barcoded beads can be disposed on a substrate in a form of a monolayer, where each barcoded bead in the plurality of barcoded beads occupies a distinct position on the substrate.
  • the method includes hybridizing, while the at least a portion of the biological sample is aligned with the array, (i) the oligonucleotide of each analyte capture agent in the first subset of the plurality of analyte capture agents, which specifically bound the first subset of analytes, to the capture domain sequence of a capture probe in a respective capture probe plurality; and (ii) the oligonucleotide of each analyte capture agent in the second subset of the plurality of analyte capture agents, which non- specifically associated with the biological sample, to the capture domain sequence of a capture probe in a respective capture probe plurality.
  • the biological sample is mounted on a second substrate.
  • a separation distance is maintained between the first substrate and the second substrate.
  • the separation distance is less than 50 microns as measured in a direction orthogonal to the surface of the second substrate.
  • the separation distance is between 1 micron and 25 microns or between 2 microns and 10 microns as measured in a direction orthogonal to the surface of the second substrate.
  • FIG. 9 illustrates this separation distance with the annotation gap 905.
  • the first substate and the second substrate are coplanar.
  • the method includes determining, using the plurality of spatial barcodes, (a) for each respective spatially barcoded feature in the array, for each respective analyte capture agent in the first and second subset of the plurality of analyte capture agents, a respective raw count of the respective analyte capture agent whose oligonucleotide hybridized to the respective spatially barcoded feature; and (b) for each respective spatially barcoded feature in the array, for each respective analyte capture agent in the first subset of the plurality of analyte capture agents, normalize the respective raw count of the respective analyte capture agent by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature, thereby obtaining a normalized count for each respective analyte capture agent in the first subset of the plurality of analyte capture agents
  • what is determined in block 1162 is (i) how many of the capture probes in the respective capture probe plurality for the given spatially barcoded feature bound to the oligonucleotide associated with analyte capture agent A, (ii) how many of the capture probes in the respective capture probe plurality for the given spatially barcoded feature bound to the oligonucleotide associated with analyte capture agent B, (iii) how many of the capture probes in the respective capture probe plurality for the given spatially barcoded feature bound to the oligonucleotide associated with analyte capture agent C, and (iv) how many of the capture probes in the respective capture probe plurality for the given spatially barcoded feature bound to the oligonucleotide associated with analyte capture agent D.
  • Counts (i) through (iv) are respectively the raw counts of the respective analyte capture agent A, B, C, and D for the given spatially barcoded feature.
  • block 1162 determines a separate raw count for analyte capture agent A, B, C, and D for each spatially barcoded feature in the array.
  • block 1162 determines (i) 1000 raw counts for analyte capture agent A, each such raw count for a different spatially barcoded feature in the array, (ii) 1000 raw counts for analyte capture agent B, each such raw count for a different spatially barcoded feature in the array, (iii) 1000 raw counts for analyte capture agent C, each such raw count for a different spatially barcoded feature in the array, and (iv) 1000 raw counts for analyte capture agent D, each such raw count for a different spatially barcoded feature in the array.
  • analyte capture agents, A, B, C, and D are distinguishable from each other in the counting process because they each have a unique analyte binding moiety barcode 516.
  • the respective raw count of the respective analyte capture agent comprises a UMI count.
  • the UMI provides one way for block 1162 to reliably determine raw counts (e.g., which capture probe has bound to an oligonucleotide from a respective analyte capture agent 526).
  • the disclosed methodology gives rise to a unique sequenced oligonucleotide (not shown in FIG. 1 or FIG. 5) each time an analyte capture agent 526 binds to a capture probe 102 / 524 on the array.
  • this unique sequenced oligonucleotide includes the analyte binding moiety barcode 516 from the analyte capture agent 526, as well as the UMI sequence 106 / 510 and the spatial barcode 105 / 508 from the coupled capture probe 524.
  • Detection of the unique sequenced oligonucleotide having this combination of a particular analyte binding moiety barcode 516, a particular UMI 106 / 510 and a particular spatial barcode 105 / 508 means that a particular analyte capture agent (one that has the particular analyte binding moiety barcode 516) has been captured by the capture domain sequence of a particular capture probe in a capture probe plurality (identified by the spatial barcode 105 /508 that uniquely identifies that capture probe plurality and the UMI 510 which uniquely identifies a particular capture probe in that capture probe plurality) for a particular spatially barcoded feature.
  • each capture probe 524 in a particular capture probe plurality has the same spatial barcode 105 / 508.
  • the same capture probe is not counted twice (for example in instances where two oligonucleotides are sequenced that have the same binding moiety barcode 516, same UMI 106 / 510 and a particular spatial barcode 105 / 508, only one count is attributed since the two oligonucleotides both represent the same capture probe / analyte capture agent binding event.
  • block 1164 increments the raw count for the corresponding capture probe for the corresponding spatially barcoded feature by a single count. If 37 oligonucleotides having this unique combination of UMI 510 and binding moiety barcode 516 are sequenced, the raw count for the analyte capture agent 526 associated with the binding moiety barcode 516 is assigned a raw count of 37 for the spatially barcoded feature associated with UMI 510.
  • Blocks 1222 and 1224 further illustrate how polynucleotides are generated and sequences that contain both an analyte binding moiety barcode of a first analyte capture agent and a sequence of a first spatial barcode in the plurality of spatial barcodes.
  • the raw count of each of the analyte capture agents in the first subset of analyte capture agents for the respective spatially barcoded feature is normalized by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature.
  • an example of such normalization would be to use the raw counts of C and D to normalize the raw count of A, and to also use the raw counts of C and D to normalize the raw count of B.
  • such normalization occurs independently for each spatially barcoded feature.
  • the normalization comprises dividing the respective raw count of the respective analyte capture agent (in the first subset of the analyte capture agents) by the sum of the raw count of the one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature. For instance, dividing the raw count of analyte capture agent A by the sum of the raw counts of analyte capture agents C and D. To provide a quantitative example, consider the case where the raw counts of analyte capture agents A, C and D are respectively 1200, 1400, and 1000 for a particular spatially barcoded feature.
  • the normalized count for analyte capture agent A is then 1200 / [1400 + 1000], or 0.5.
  • the product, in this example “0.5” is multiplied by a constant factor.
  • the same constant factor is used for each normalization for each spatially barcoded feature in such embodiments.
  • the purpose of the use of this constant factor is to bring all normalized counts into a suitable range of values (e.g., whole integer values).
  • the final normalized value for analyte capture agent A for the particular spatially barcoded feature in this example is 0.5 * 1000, or 500.
  • a constant factor is used, as discussed above.
  • the constant factor is a value greater than 1.
  • the constant factor is a value between 5 and 100,000.
  • the constant factor is a value between 10 and 10,000.
  • the constant factor is a value between 100 and 2,000.
  • normalizing the respective raw count of the respective analyte capture agent by the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature comprises dividing the respective raw count of the respective analyte capture agent by a measure of central tendency of the raw count of the one or more analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature.
  • the raw counts of analyte capture agents A, C and D are respectively 1200, 1400, and 1000 for a particular spatially barcoded feature.
  • the product, in this example “1” is multiplied by a constant factor.
  • the same constant factor is used for each normalization for each spatially barcoded feature in such embodiments.
  • the purpose of the use of this constant factor is to bring all normalized counts into a suitable range of values (e.g., whole integer values).
  • the final normalized value for analyte capture agent A for the particular spatially barcoded feature in this example is 1 * 1000, or 1000.
  • the measure of central tendency is a mean, median, mode, a weighted mean, weighted median, or weighted mode of the raw count of the one or more (e.g., two or more) analyte capture agents in the second subset of the plurality of analyte capture agents in the respective spatially barcoded feature.
  • the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents consists of a raw count of between 2 capture agents and 20 capture agents in the second subset of the plurality of analyte capture agents.
  • the raw count of one or more analyte capture agents in the second subset of the plurality of analyte capture agents consists of a raw count of two or more, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 capture agents in the second subset of the plurality of analyte capture agents.
  • the first subset of analytes are proteins and the plurality of analytes further comprises a second subset of analytes that are nucleic acids.
  • Some such embodiments support interrogating a biological sample using both antibodies that bind to particular antigens (see, for example, section (c) entitled “Capturing Analytes for Spatial Detection using Analyte Capture Agents”, above), and probes that detect transcription products (e.g., in the form or mRNA) (see section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation”, above) .
  • the method further comprises contacting a first probe and a second probe to the biological sample under conditions suitable for hybridization of the first probe and the second probe to an analyte in the second subset of analytes.
  • the first probe comprises a sequence that is substantially complementary to a first portion of a sequence of the analyte.
  • the second probe comprises a sequence that is substantially complementary to a second portion of a sequence of the analyte.
  • the second or the first probe comprises a sequence that is complementary to the capture domain sequence of the capture probe in a respective capture probe plurality. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation”, above.
  • the first portion of the sequence of the analyte and the second portion of the sequence of the analyte are a contiguous nucleic acid sequence of the analyte.
  • the first portion of the sequence of the analyte and the second portion of the sequence of the analyte are at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more nucleotides away from one another in the analyte. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation” above, for more disclosure on such embodiments.
  • the biological sample is contacted with a set of about 5-100,000 probes, where the set comprises the first probe and the second probe.
  • the method further comprises coupling the first probe and the second probe, thereby generating a connected probe, and hybridizing the connected probe to the capture domain sequence of one or more of the capture probes in one or more capture probe pluralities in the array. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation” above, for more disclosure on such embodiments.
  • the coupling the first probe and the second probe comprises ligating, via a ligase, the first probe and the second probe.
  • the ligase is selected from the group consisting of splintR ligase, a single stranded DNA ligase, and a T4 DNA ligase. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation” above, for more disclosure on such embodiments.
  • the method further comprises treating the biological sample with a reagent medium comprising a permeabilization agent, thereby permeabilizing the biological sample.
  • the permeabilization agent comprises a protease.
  • the protease is selected from trypsin, pepsin, elastase, or proteinase K. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA-Templated Ligation” above, for more disclosure on such embodiments.
  • the method further comprises treating the biological sample with a releasing agent, thereby releasing the connected probe from the biological sample.
  • the releasing agent comprises a nuclease.
  • the nuclease comprises an RNase, optionally where the RNase is selected from RNase A, RNase C, RNase H, or RNase I. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA- Templated Ligation” above, for more disclosure on such embodiments.
  • the reagent medium further comprises a detergent. See, for example, section (b) “Capturing Nucleic Acid Analytes using RNA- Templated Ligation”, above for more disclosure on such embodiments.
  • the first and second probe oligonucleotides hybridize to genomic DNA (gDNA) which can lead to Unique Molecular Identifier (UMI) counts from probe ligation events on gDNA (off target) in addition to the desired (on target) probe ligation events on a target nucleic acid e.g., mRNA.
  • the method further comprises treating the biological sample with a deoxyribonuclease (DNase).
  • DNase can be an endonuclease or exonuclease.
  • the DNase digests single- and/or double-stranded DNA. Suitable DNases include, without limitation, a DNase I and a DNase II.
  • the method further comprises overlaying the histological image onto a second image comprising a normalized count for at least one analyte capture agent in the first subset of the plurality of analyte capture agents for each respective spatially barcoded feature in the array.
  • Example 1 illustrates the benefits of the disclosed normalized process. Methods for taking histological images are disclosed in PCT Publication No. W02023/044071, which is hereby incorporated by reference. Thus, in such embodiments, the histological image and the second image are put in the same frame of reference with respect to the biological sample. This allows for the observer to notice any spatial correlations between features in the histological image and features in the second image.
  • a feature In the context of an image, a feature is some region of high or low intensity. Correlations in such spatial features signifies some association between features observable in histological images and the spatial abundance of the antigen or antigens associated with the analyte capture agents whose normalized counts were used to create the second image.
  • the second image comprises an array of values, where each element in the array of values has (i) the coordinates of the location of the corresponding spatially barcoded feature in the array of spatially barcoded features and (ii) the normalized count of the analyte capture agent “A” in the corresponding spatially barcoded feature.
  • the normalized count of each analyte capture agent in the first subset of analyte capture agents is summed together to provide a total count for each of the spatially barcoded features and these total count values are used to form the second image.
  • the second image comprises an array of values, where each element in the array of values has (i) the coordinates of the location of the corresponding spatially barcoded feature in the array of spatially barcoded features and (ii) the summed normalized count of each of the analyte capture agent in the first subset of analyte capture agents for the corresponding spatially barcoded feature.
  • the histological image is overlayed onto this second image. In other embodiments the histological image is optional. In other embodiments the histological image is not generated.
  • the method comprises taking a histological image of the biological sample, and overlaying the histological image onto a second image comprising a normalized count for at least one analyte capture agent in the second subset of the plurality of analyte capture agents for each respective spatially barcoded feature in the array.
  • This differs from block 1208 in that, rather than using normalized counts of an analyte capture agent in the first subset of analyte capture agents, a raw count of an analyte capture agent in the second subset of analyte capture agents is used.
  • Block 1204 has application in quality control, for example, visually observing the degree to which a particular analyte capture agent in the second subset of analyte capture agents is normalizing as well as the spatial context of such normalization.
  • FIG. 14 illustrates a second image (unnormalized image) overlayed on a histological image.
  • second image 1402 is overlaid on a histological image 1404 of the same biological sample.
  • Each circle in second image 1402 represents a respective spatially barcoded feature in the array.
  • each respective circle in the array represents a total raw count of a particular analyte capture agent whose oligonucleotide hybridized to a capture probe of the respective spatially barcoded feature in accordance with the shade code to the right of the image.
  • an image based on a normalized count of one analyte capture agent in the first subset of analyte capture agents or a raw count of one analyte capture agent in the second subset of analyte capture agents is generated and observed without determining a histological image of the biological sample.
  • the histological image comprises 10,000 or more pixel values.
  • the second image comprises 10,000 or more pixel values.
  • the overlaying between the histological image and the second image takes into consideration an alignment of at least one percent of the pixels in the histological image with corresponding pixels in the second image.
  • the histological image comprises 100,000 or more pixel values while the second image comprises 100,000 or more pixel values.
  • the overlaying takes into consideration an alignment of at least one percent of the pixels in the histological image with corresponding pixels in the second image.
  • the histological image comprises 500,000 or more pixel values and the second image comprises 500,000 or more pixel values.
  • the overlaying takes into consideration an alignment of at least one percent of the pixels in the histological image with corresponding pixels in the second image.
  • the histological image comprises 250,000, 750,000, 1 x 10 6 , 2 x 10 6 , 3 x 10 6 , 4 x 10 6 or more pixel values and the second image comprises 250,000, 750,000, 1 x 10 6 , 2 x 10 6 , 3 x 10 6 , 4 x 10 6 or more pixel values.
  • the overlaying takes into consideration an alignment of at least one percent, two percent, three percent, four percent, five percent, six percent, seven percent, eight percent, nine percent, or ten percent of the pixels in the histological image with corresponding pixels in the second image.
  • the histological image comprises 250,000, 750,000, 1 x 10 6 , 2 x 10 6 , 3 x 10 6 , 4 x 10 6 or more pixel values and the second image comprises 250,000, 750,000, 1 x 10 6 , 2 x 10 6 , 3 x 10 6 , 4 x 10 6 or more pixel values.
  • the overlaying takes into consideration an alignment of at least 5 percent, 10 percent, 15 percent, 20 percent, 25 percent, 30 percent, 35 percent, or 40 percent of the pixels in the histological image with corresponding pixels in the second image.
  • a histological image generally refers to any image that contains structural information for a biological sample and/or a biological tissue.
  • a histological image is obtained using any detectable marker such as an antibody, a fluorescent label (e.g., a fluorophore), a radioactive label, a chemiluminescent label, a calorimetric label, a colorimetric label, a stain and/or a combination thereof.
  • the biological sample is prepared for taking a histological image using a stain selected from the group consisting of: live/dead stain, trypan blue, periodic acid-Schiff reaction stain, Masson’s trichrome, Alcian blue, van Gieson, reticulin, Azan, Giemsa, Toluidine blue, isamin blue, Sudan black and osmium, acridine orange, Bismarck brown, carmine, Coomassie blue, cresyl violet, DAPI, eosin, ethidium bromide, acid fuchsine, hematoxylin, Hoechst stains, iodine, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide, propidium iodide, rhodamine, safranin, or a combination thereof.
  • a stain selected from the group consisting of: live/dead stain, try
  • a histological image is acquired using transmission light microscopy (e.g., bright field transmission light microscopy, dark field transmission light microscopy, oblique illumination transmission light microscopy, dispersion staining transmission light microscopy, phase contrast transmission light microscopy, differential interference contrast transmission light microscopy, emission imaging, etc.).
  • transmission light microscopy e.g., bright field transmission light microscopy, dark field transmission light microscopy, oblique illumination transmission light microscopy, dispersion staining transmission light microscopy, phase contrast transmission light microscopy, differential interference contrast transmission light microscopy, emission imaging, etc.
  • a histological image is a bright-field microscopy image in which the imaged biological sample appears dark on a bright background.
  • the biological sample has been stained.
  • the biological sample has been stained with Hematoxylin and Eosin and the histological image is a bright-field microscopy image.
  • the biological sample has been stained with a Periodic acid-Schiff reaction stain (stains carbohydrates and carbohydrate rich macromolecules a deep red color) and the histological image is a bright-field microscopy image.
  • the biological sample has been stained with a Masson’s tri chrome stain (nuclei and other basophilic structures are stained blue, cytoplasm, muscle, erythrocytes and keratin are stained bright-red, collagen is stained green or blue, depending on which variant of the technique is used) and the histological image is a bright-field microscopy image.
  • the biological sample has been stained with an Alcian blue stain (a mucin stain that stains certain types of mucin blue, and stains cartilage blue and can be used with H&E, and with van Gieson stains) and the histological image is a bright-field microscopy image.
  • the biological sample has been stained with a van Gieson stain (stains collagen red, nuclei blue, and erythrocytes and cytoplasm yellow, and can be combined with an elastin stain that stains elastin blue/black) and the histological image is a bright-field microscopy image.
  • the biological sample has been stained with a reticulin stain, an Azan stain, a Giemsa stain, a Toluidine blue stain, an isamin blue/eosin stain, a Nissl and methylene blue stain, and/or a Sudan black and osmium stain and the histological image is a bright-field microscopy image.
  • the histological image is an immunohistochemistry (IHC) image.
  • IHC imaging may utilize a staining technique using antibody labels.
  • One form of immunohistochemistry (IHC) imaging is immunofluorescence (IF) imaging.
  • IF imaging primary antibodies are used that specifically label a protein in the biological sample, and then a fluorescently labelled secondary antibody or other form of probe is used to bind to the primary antibody, to show up where the first (primary) antibody has bound.
  • a light microscope, equipped with fluorescence is used to visualize the staining. The fluorescent label is excited at one wavelength of light and emits light at a different wavelength.
  • a biological sample is exposed to several different primary antibodies (or other forms of probes) in order to quantify several different proteins in a biological sample.
  • each such respective different primary antibody (or probe) is then visualized with a different fluorescence label (different channel) that fluoresces at a unique wavelength or wavelength range (relative to the other fluorescence labels used). In this way, several different proteins in the biological sample can be visualized.
  • fluorescence imaging in addition to bright- field imaging or instead of bright-field imaging, fluorescence imaging is used to acquire a respective image of the biological sample.
  • fluorescence imaging refers to imaging that relies on the excitation and re-emission of light by fluorophores, regardless of whether they are added experimentally to the sample and bound to antibodies (or other compounds) or naturally occurring features of the sample.
  • IHC imaging, and in particular IF imaging is just one form of fluorescence imaging.
  • a histological image is acquired using confocal microscopy, two-photon imaging, wide-field multiphoton microscopy, single plane illumination microscopy or light sheet fluorescence microscopy.
  • confocal microscopy See, for example, Adaptive Optics for Biological Imaging, 2013, Kubby ed., CRC Press, Boca Raton, Florida; and Confocal and Two-Photon Microscopy: Foundations, Applications and Advances, 2002, Diaspro ed., Wiley Liss, New York, New York; and Handbook of Biological Confocal Microscopy, 2002, Pawley ed., Springer Science+Business Media, LLC, New York, New York each of which is hereby incorporated by reference.
  • a histological image is obtained using various immunohistochemistry (IHC) probes that excite at various different wavelengths.
  • IHC immunohistochemistry
  • An image can be obtained in any electronic image file format, including but not limited to JPEG/JFIF, TIFF, Exif, PDF, EPS, GIF, BMP, PNG, PPM, PGM, PBM, PNM, WebP, HDR raster formats, HEIF, BAT, BPG, DEEP, DRW, ECW, FITS, FLIF, ICO, ILBM, IMG, PAM, PCX, PGF, JPEG XR, Layered Image File Format, PLBM, SGI, SID, CD5, CPT, PSD, PSP, XCF, PDN, CGM, SVG, PostScript, PCT, WMF, EMF, SWF, XAML, and/or RAW.
  • a histological image is obtained in any electronic color mode, including but not limited to grayscale, bitmap, indexed, RGB, CMYK, HSV, lab color, duotone, and/or multichannel.
  • the image is manipulated (e.g., stitched, compressed and/or flattened).
  • the histological image is a color image (e.g., 3 x 8 bit, 2424 x 2424 pixel resolution).
  • the histological is a monochrome image (e.g., 14 bit, 2424 x 2424 pixel resolution).
  • a histological image comprises a plurality of pixels.
  • the plurality of pixels comprises at least 100, at least 500, at least 1000, at least 5000, at least 10,000, at least 50,000, at least 100,000, at least 500,000, at least 1 x 10 6 , at least 2 x 10 6 , at least 3 x 10 6 , at least 5 x 10 6 , at least 8 x 10 6 , at least 1 x 10 7 , at least 1 x 10 8 , at least 1 x 10 9 , at least 1 x 10 10 , or at least 1 x 10 11 pixels.
  • the plurality of pixels comprises no more than 1 x 10 12 , no more than 1 x 10 11 , no more than 1 x 10 10 , no more than 1 x 10 9 , no more than 1 x 10 8 , no more than 1 x 10 7 , no more than 1 x 10 6 , no more than 100,000, no more than 10,000, or no more than 1000 pixels.
  • the plurality of pixels comprises from 1000 to 100,000, from 10,000 to 500,000, from 100,000 to 1 x 10 6 , from 500,000 to 1 x 10 9 , or from 1 x 10 6 to 1 x 10 8 pixels.
  • the plurality of pixels falls within another range starting no lower than 100 pixels and ending no higher than 1 x 10 12 pixels.
  • each pixel in the plurality of pixels of the histological image has a pixel size (resolution) between 0.8pm and 4.0pm. In some embodiments this pixel size is derived by dividing the camera pixel size (resolution) by the magnification of the objective lens of the camera used to capture values for the plurality of pixels. In some embodiments, each pixel in the plurality of pixels has a pixel size between 0.4pm and 5.0pm. In some embodiments, each pixel in the plurality of pixels of the first image has a pixel size (resolution) between 0.8pm and 4.0pm or between 0.4pm and 5.0pm.
  • a histological image comprises a plurality of pixels, such that the location of each respective pixel in the plurality of pixels in the array (e.g., matrix) corresponds to its original location in the image.
  • a histological image is represented as a vector comprising a plurality of pixels, such that each respective pixel in the plurality of pixels in the vector comprises spatial information corresponding to its original location in the image.
  • the plurality of pixels in a histological image corresponds to the location of each spatially barcoded feature in the array of spatially barcoded features.
  • each spatially barcoded feature in the array of spatially barcoded features is represented by five or more, ten or more, 100 or more, 1000 or more, 10,000 or more, 50,000 or more, 100,000 or more, or 200,000 or more contiguous pixels in a respective histological image.
  • each spatially barcoded feature in the array of spatially barcoded features is represented by no more than 500,000, no more than 200,000, no more than 100,000, no more than 50,000, no more than 10,000, or no more than 1000 contiguous pixels in a respective histological image.
  • each spatially barcoded feature in the array of spatially barcoded features is represented by between 1000 and 250,000, between 100,000 and 500,000, between 10,000 and 100,000, or between 5000 and 20,000 contiguous pixels in a respective histological image. In some embodiments, each spatially barcoded feature in the array of spatially barcoded features is represented by a range of contiguous pixels in a histological image starting no lower than 5 pixels and ending no higher than 500,000 pixels.
  • a histological image has an image size between 1 KB and 1 MB, between 1 MB and 0.5 GB, between 0.5 GB and 5 GB, between 5 GB and 10 GB, or greater than 10 GB.
  • a histological image is obtained using an image capture device, such as a microscope.
  • the method further comprises using the normalized count for each respective analyte capture agent in the first subset of the plurality of analyte capture agents and the count for each respective analyte capture agent in the second subset of the plurality of analyte capture agents for each respective spatially barcoded feature in the array to determine whether or not the subject has a condition.
  • any of the spatial analyte data acquired using the disclosed methods is used to determine whether or not the subject has a disease or a stage of a disease.
  • the spatial analyte data is used to determine a probability or likelihood that the subject has a disease or a stage of a disease.
  • the disease is cancer or diabetes.
  • the disease is a cancer, hematologic disorder, autoimmune disease, inflammatory disease, immunological disorder, metabolic disorder, neurological disorder, genetic disorder, psychiatric disorder, gastroenterological disorder, renal disorder, cardiovascular disorder, dermatological disorder, respiratory disorder, or a viral infection.
  • the method further comprises providing a treatment to the subject when it is determined that the subject has the condition.
  • the treatment comprises a composition comprising a small molecule compound and one or more excipient and/or one or more pharmaceutically acceptable carrier and/or one or more diluent.
  • these include all conventional solvents, dispersion media, fillers, solid carriers, coatings, antifungal and antibacterial agents, dermal penetration agents, surfactants, isotonic and absorption agents and the like.
  • An exemplary carrier is pharmaceutically “acceptable” in the sense of being compatible with the other ingredients of the composition (e.g., the composition comprising the modified polymer) and not injurious to the patient.
  • the compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product.
  • Exemplary compounds, compositions, or combinations of the present disclosure e.g., the composition comprising the modified polymer
  • a compound of the invention or a pharmaceutically acceptable salt, solvate or prodrug thereof may be administered by injection or infusion.
  • the method further comprises sequencing a first polynucleotide comprising (i) a sequence of an analyte binding moiety barcode of a first analyte capture agent in the plurality of analyte capture agents or a complement thereof, and (ii) a sequence of a first spatial barcode in the plurality of spatial barcodes, or a complement thereof.
  • the method further comprises generating the first polynucleotide.
  • the generating comprises extending the capture probe in the respective capture probe plurality having the first spatial barcode using the oligonucleotide of the first analyte capture agent as a template.
  • Example 1 illustrates the benefits of the disclosed normalization process.
  • FIG. 14 illustrates an unnormalized image.
  • a second image 1402 is overlaid on a histological image 1404 of the same biological sample.
  • Each circle in the second image represents a respective spatially barcoded feature in the array.
  • the color of each respective circle in the array represents a total raw count of a particular analyte capture agent whose oligonucleotide hybridized to a capture probe of the respective spatially barcoded feature in accordance with the color code to the right of the image.
  • the data shows presence of a few regions that have disproportionately high or low expression of the protein bound by the analyte capture agent.
  • FIGS. 15A and 15B are exemplary data showing the spatial distribution of antibodies on the same tissue section before and after normalization in accordance with the present disclosure, respectively.
  • FIG. 15A shows that before normalization in accordance with the present disclosure, the tissue section appears to include a region 1502 of relatively high protein expression, as depicted by the high-intensity (e.g., yellow- and green-colored) spots.
  • FIG. 15B shows that after normalization, the region 1502 that were observed in FIG. 15A vanishes and another region 1504 of relatively high protein expression is observed on an edge of the tissue section. Absent the normalization process of the present disclosure, the region 1504 would have been masked, and an artifact (e.g., 1502) would have been assessed as genuine biological observation.
  • an artifact e.g., 1502
  • FIG. 16 illustrates an exemplary normalization pathway that utilizes the unique molecular identifier (UMI) counts of four control antibodies to reduce artifacts in the data, in accordance with some embodiments of the present disclosure.
  • UMI unique molecular identifier
  • FIGS. 17A and 17B illustrate cross-correlation data of analyte capture agents (e.g., oligonucleotide-conjugated antibodies) before and after normalization, respectively.
  • FIG. 17A shows spurious correlations before normalization.
  • FIG. 17B shows an improvement in the crosscorrelation data after normalization.
  • FIG. 18 illustrates that the normalization process described in the present disclosure aids the detection of biological structures.
  • FIGS. 19A, 19B, and 19C collectively illustrate screenshots of a user interface that provides interactive visualization functionality to analyze data in accordance with some embodiments of the present disclosure.
  • FIG. 19A illustrates the user interface 1900.
  • the user interface 1900 displays an initial screen 1902 that allows a user to see clustering identified by the application. Such clustering techniques are disclosed in United States Patent Publication No. US 2021-0062272 Al.
  • FIG. 19B illustrates a control antibody normalization screen 1904.
  • panel 1904 represents the default when analyzing data that includes antibodies.
  • FIG. 19C illustrates user interaction with a slider bar 1906, which allows a user to “gate” their data and identify area(s) of interest in the biological sample.
  • the present invention can be implemented as a computer program product that comprises a computer program mechanism embedded in a non-transitory computer readable storage medium.
  • the computer program product could contain the program modules shown in FIG. 10, and/or described in FIGS.
  • program modules can be stored on a CD-ROM, DVD, magnetic disk storage product, USB key, or any other non-transitory computer readable data or program storage product.
  • the terms “about” or “approximately” refer to an acceptable error range for a particular value as determined by one of ordinary skill in the art, which can depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. “About” can mean a range of ⁇ 20%, ⁇ 10%, ⁇ 5%, or ⁇ 1% of a given value. The term “about” or “approximately” can mean within an order of magnitude, within 5-fold, or within 2- fold, of a value.
  • each when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection, unless expressly stated otherwise, or unless the context of the usage clearly indicates otherwise.
  • the singular forms “a,” “an,” and “the” include the plural forms as well, unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only,” and the like in connection with the recitation of claim elements or use of a “negative” limitation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP24740635.8A 2023-05-15 2024-05-15 Normalisierung räumlicher antikörperdaten Pending EP4500178A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363502352P 2023-05-15 2023-05-15
PCT/US2024/029416 WO2024238625A1 (en) 2023-05-15 2024-05-15 Spatial antibody data normalization

Publications (1)

Publication Number Publication Date
EP4500178A1 true EP4500178A1 (de) 2025-02-05

Family

ID=91898608

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24740635.8A Pending EP4500178A1 (de) 2023-05-15 2024-05-15 Normalisierung räumlicher antikörperdaten

Country Status (2)

Country Link
EP (1) EP4500178A1 (de)
WO (1) WO2024238625A1 (de)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3175914A1 (de) 2004-01-07 2017-06-07 Illumina Cambridge Limited Verbesserungen in oder im zusammenhang mit molekül-arrays
WO2007002006A2 (en) 2005-06-20 2007-01-04 Panomics, Inc. Multiplex detection of nucleic acids
US20130171621A1 (en) 2010-01-29 2013-07-04 Advanced Cell Diagnostics Inc. Methods of in situ detection of nucleic acids
CA2794522C (en) 2010-04-05 2019-11-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US9012022B2 (en) 2012-06-08 2015-04-21 Illumina, Inc. Polymer coatings
US9783841B2 (en) 2012-10-04 2017-10-10 The Board Of Trustees Of The Leland Stanford Junior University Detection of target nucleic acids in a cellular sample
CA2886974C (en) 2012-10-17 2021-06-29 Spatial Transcriptomics Ab Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
WO2014210225A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US20150000854A1 (en) 2013-06-27 2015-01-01 The Procter & Gamble Company Sheet products bearing designs that vary among successive sheets, and apparatus and methods for producing the same
CN105658310A (zh) 2013-09-13 2016-06-08 斯坦福大学托管董事会 使用质量标签和次级离子质谱术的组织复用成像
WO2015161173A1 (en) 2014-04-18 2015-10-22 William Marsh Rice University Competitive compositions of nucleic acid molecules for enrichment of rare-allele-bearing species
WO2016007839A1 (en) 2014-07-11 2016-01-14 President And Fellows Of Harvard College Methods for high-throughput labelling and detection of biological features in situ using microscopy
US20160108458A1 (en) 2014-10-06 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Multiplexed detection and quantification of nucleic acids in single-cells
US9727810B2 (en) 2015-02-27 2017-08-08 Cellular Research, Inc. Spatially addressable molecular barcoding
ES2955916T3 (es) 2015-04-10 2023-12-11 Spatial Transcriptomics Ab Análisis múltiplex de especímenes biológicos de ácidos nucleicos espacialmente distinguidos
US10059990B2 (en) 2015-04-14 2018-08-28 Massachusetts Institute Of Technology In situ nucleic acid sequencing of expanded biological samples
CN107709574B (zh) 2015-04-14 2021-10-01 皇家飞利浦有限公司 生物组织样品的分子概况的空间作图
US20180057873A1 (en) * 2015-04-17 2018-03-01 Centrillion Technology Holdings Corporation Methods for performing spatial profiling of biological materials
US10640816B2 (en) 2015-07-17 2020-05-05 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
EP3957747A1 (de) 2015-07-27 2022-02-23 Illumina, Inc. Räumliche zuordnung von nukleinsäuresequenzen
US10364457B2 (en) 2015-08-07 2019-07-30 Massachusetts Institute Of Technology Nanoscale imaging of proteins and nucleic acids via expansion microscopy
EP3332258B1 (de) 2015-08-07 2020-01-01 Massachusetts Institute of Technology Expansionsmikroskopie unter proteinrückhaltung
US20170241911A1 (en) 2016-02-22 2017-08-24 Miltenyi Biotec Gmbh Automated analysis tool for biological specimens
EP4354140A3 (de) 2016-02-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Multiplexierte einzelmolekül-rna-visualisierung mit einem zwei-sonden-proximitätsligationssystem
WO2017222453A1 (en) 2016-06-21 2017-12-28 Hauling Thomas Nucleic acid sequencing
US10593967B2 (en) 2016-06-30 2020-03-17 Honeywell International Inc. Modulated thermal conductance thermal enclosure
EP4180533A1 (de) 2016-07-27 2023-05-17 The Board of Trustees of the Leland Stanford Junior University Hochmultiplexierte fluoreszenzbildgebung
EP4428536A3 (de) 2016-08-31 2024-12-04 President and Fellows of Harvard College Verfahren zur kombination des nachweises von biomolekülen in einem einzigen test mit fluoreszenter in-situ-sequenzierung
EP3507364A4 (de) 2016-08-31 2020-05-20 President and Fellows of Harvard College Verfahren zur erstellung von bibliotheken von nukleinsäuresequenzen zur detektion mittels in-situ-fluoreszenzsequenzierung
US11505819B2 (en) 2016-09-22 2022-11-22 William Marsh Rice University Molecular hybridization probes for complex sequence capture and analysis
GB201619458D0 (en) 2016-11-17 2017-01-04 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
WO2018107054A1 (en) 2016-12-09 2018-06-14 Ultivue, Inc. Improved methods for multiplex imaging using labeled nucleic acid imaging agents
US10995361B2 (en) 2017-01-23 2021-05-04 Massachusetts Institute Of Technology Multiplexed signal amplified FISH via splinted ligation amplification and sequencing
US11597965B2 (en) 2017-10-06 2023-03-07 10X Genomics, Inc. RNA templated ligation
US11753676B2 (en) 2017-10-11 2023-09-12 Expansion Technologies Multiplexed in situ hybridization of tissue sections for spatially resolved transcriptomics with expansion microscopy
EP3715493A4 (de) 2017-12-27 2020-11-25 JFE Steel Corporation Hochfestes stahlblech und verfahren zur herstellung davon
WO2019213254A1 (en) 2018-05-02 2019-11-07 The General Hospital Corporation High-resolution spatial macromolecule abundance assessment
WO2020008066A1 (en) * 2018-07-06 2020-01-09 Institut Pasteur Human immune system mouse model
CN113016168B (zh) 2018-09-17 2023-12-08 施耐德电子系统美国股份有限公司 工业系统事件检测和对应的响应
WO2020061066A1 (en) 2018-09-17 2020-03-26 Computer World Services Corp. dba LabSavvy Systems and methods for automated reporting and education for laboratory test results
US20220025447A1 (en) 2018-12-10 2022-01-27 10X Genomics, Inc. Generating spatial arrays with gradients
US20210189475A1 (en) 2018-12-10 2021-06-24 10X Genomics, Inc. Imaging system hardware
US20220267844A1 (en) * 2019-11-27 2022-08-25 10X Genomics, Inc. Methods for determining a location of a biological analyte in a biological sample
EP3931354A1 (de) 2019-02-28 2022-01-05 10X Genomics, Inc. Profilierung von biologischen analyten mit räumlich barcodierten oligonukleotid-arrays
US20230159995A1 (en) * 2019-02-28 2023-05-25 10X Genomics, Inc. Profiling of biological analytes with spatially barcoded oligonucleotide arrays
US20210062272A1 (en) 2019-08-13 2021-03-04 10X Genomics, Inc. Systems and methods for using the spatial distribution of haplotypes to determine a biological condition
US11514575B2 (en) 2019-10-01 2022-11-29 10X Genomics, Inc. Systems and methods for identifying morphological patterns in tissue samples
US20220389409A1 (en) 2019-11-11 2022-12-08 The Broad Institute, Inc. High-resolution spatial and quantitative dna assessment
US12154266B2 (en) 2019-11-18 2024-11-26 10X Genomics, Inc. Systems and methods for binary tissue classification
AU2020388573A1 (en) 2019-11-21 2022-06-23 10X Genomics, Inc, Spatial analysis of analytes
CN115023734B (zh) 2019-11-22 2023-10-20 10X基因组学有限公司 使用基准对齐对分析物进行空间分析的系统和方法
WO2021133849A1 (en) 2019-12-23 2021-07-01 10X Genomics, Inc. Methods for spatial analysis using rna-templated ligation
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
US20240378734A1 (en) 2021-09-17 2024-11-14 10X Genomics, Inc. Systems and methods for image registration or alignment

Also Published As

Publication number Publication date
WO2024238625A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
US11873482B2 (en) Methods, compositions, and systems for spatial analysis of analytes in a biological sample
US20230332247A1 (en) Methods, compositions, and systems for capturing analytes from glioblastoma samples
US20240271195A1 (en) Methods, compositions, and systems for capturing probes and/or barcodes
WO2023150163A1 (en) Methods, compositions, and systems for capturing analytes from lymphatic tissue
US12195790B2 (en) Methods for improved in situ detection of nucleic acids and spatial analysis
US12071655B2 (en) Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2023150098A1 (en) Methods, kits, compositions, and systems for spatial analysis
EP4062372B1 (de) Systeme und verfahren zur räumlichen analyse von analyten unter verwendung von referenzmarkerausrichtung
US20240218427A1 (en) Methods, compositions, and systems for enhancing spatial analysis of analytes in a biological sample
US12031177B1 (en) Methods of enhancing spatial resolution of transcripts
WO2024145441A1 (en) Methods, compositions, and kits for determining a location of a target nucleic acid in a fixed biological sample
WO2024206603A1 (en) Methods, compositions, and kits for reducing analyte mislocalization
WO2024220882A1 (en) Methods and compositions for detecting nucleic acids in a fixed biological sample
US20230306593A1 (en) Systems and methods for spatial analysis of analytes using fiducial alignment
US20230140008A1 (en) Systems and methods for evaluating biological samples
WO2024238625A1 (en) Spatial antibody data normalization
US20240052404A1 (en) Systems and methods for immunofluorescence quantification
US20250075261A1 (en) Spatial arrays containing capture probes with different release mechanisms
US20240368678A1 (en) Methods and compositions for spatial assay
EP4515492A1 (de) Systeme und verfahren zur beurteilung biologischer proben
WO2024036191A1 (en) Systems and methods for colocalization
WO2025029605A1 (en) Methods and compositions for detecting genetic variants using capture probes and primer extension

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR